CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | purine ribonucleotide |
|
Accession: | CHEBI:26400
|
browse the term
|
Definition: | Any ribonucleotide that has a purine nucleobase. |
Synonyms: | related_synonym: | purine ribonucleotides |
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression multiple interactions |
ISO |
Cyclic AMP results in increased expression of ABCA1 mRNA; Cyclic AMP results in increased expression of ABCA1 protein [HCAR2 protein results in decreased abundance of Cyclic AMP] which results in decreased expression of ABCA1 protein |
CTD |
PMID:20339114 PMID:20655299 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases transport multiple interactions affects uptake |
ISO |
ABCC4 protein results in increased transport of Cyclic AMP Probenecid affects the reaction [ABCC4 protein affects the uptake of Cyclic AMP analog] |
CTD |
PMID:11856762 PMID:28587784 |
|
NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
multiple interactions |
ISO |
[ADCYAP1 protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:7733904 |
|
NCBI chr 9:121,705,897...121,725,736
Ensembl chr 9:121,706,979...121,725,716
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases abundance |
ISO |
ADIPOQ protein results in increased abundance of Cyclic AMP |
CTD |
PMID:18931039 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
Adm |
adrenomedullin |
multiple interactions increases abundance |
EXP |
ADM protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]; CALCA protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]; Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP] ADM protein results in increased abundance of Cyclic AMP; ADM results in increased abundance of Cyclic AMP |
CTD |
PMID:10374718 PMID:17306419 |
|
NCBI chr 1:175,443,189...175,447,260
Ensembl chr 1:175,445,088...175,447,259
|
|
G |
Adra1b |
adrenoceptor alpha 1B |
multiple interactions |
ISO |
ADRA1B protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP] |
CTD |
PMID:12649302 |
|
NCBI chr10:29,392,762...29,450,644
Ensembl chr10:29,392,762...29,450,644
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions increases abundance affects abundance |
ISO EXP |
[3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Bupranolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Epinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Metoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Propranolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Propranolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; ADRB1 protein polymorphism affects the reaction [[Carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP]; Alprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bisoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bupranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Carvedilol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; Isoproterenol promotes the reaction [ADRB1 protein results in increased abundance of Cyclic AMP]; Metoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Nadolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Oxprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Pindolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Sotalol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Timolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP] ADRB1 protein affects the abundance of Cyclic AMP; ADRB1 protein polymorphism affects the abundance of Cyclic AMP ADRB1 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP] |
CTD |
PMID:11562432 PMID:12761341 PMID:14502278 PMID:14730417 PMID:15060759 PMID:17200720 PMID:18378355 PMID:18787115 PMID:19419905 |
|
NCBI chr 1:277,537,585...277,538,985
Ensembl chr 1:277,537,585...277,538,985
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions increases chemical synthesis increases abundance affects abundance |
EXP ISO |
[Terbutaline results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; ADRB2 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP] ADRB2 protein polymorphism results in increased chemical synthesis of Cyclic AMP; ADRB2 protein results in increased chemical synthesis of Cyclic AMP [Acebutolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Betaxolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [BRL 37344 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [broxaterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [carvedilol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [carvedilol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Isoproterenol results in increased activity of ADRB2 protein] which results in increased chemical synthesis of Cyclic AMP; [Labetalol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Metaproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Metoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Metoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Nadolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Oxprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Practolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Propranolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Propranolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Sotalol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Timolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; Atenolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP] ADRB2 protein results in increased abundance of Cyclic AMP ADRB2 protein affects the abundance of Cyclic AMP |
CTD |
PMID:10516654 PMID:10857765 PMID:10952688 PMID:11562432 PMID:12920204 PMID:14730417 PMID:16036225 PMID:16980553 PMID:17925438 PMID:18378355 PMID:19419905 PMID:21868359 PMID:27825928 |
|
NCBI chr18:57,513,792...57,515,834
Ensembl chr18:57,513,793...57,515,834
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions affects abundance |
ISO |
3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate inhibits the reaction [[SR 59119A binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP]; [Albuterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [BRL 37344 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [broxaterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [Epinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [SR 59119A binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Terbutaline binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP ADRB3 protein affects the abundance of Cyclic AMP |
CTD |
PMID:10952688 PMID:14730417 |
|
NCBI chr16:69,003,541...69,006,632
Ensembl chr16:69,003,868...69,006,632
|
|
G |
Ahcyl1 |
adenosylhomocysteinase-like 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of AHCYL1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:210,438,884...210,474,350
Ensembl chr 2:210,438,893...210,473,761
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions decreases expression |
EXP |
AHR protein promotes the reaction [Cyclic AMP results in increased expression of CYP1B1 mRNA]; Cyclic AMP inhibits the reaction [AHR protein binds to ARNT protein]; Cyclic AMP promotes the reaction [AHR protein binds to CYP1B1 enhancer] Cyclic AMP results in decreased expression of AHR protein |
CTD |
PMID:12859982 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Alpp |
alkaline phosphatase, placental |
multiple interactions |
ISO |
[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of ALPP mRNA |
CTD |
PMID:16036225 |
|
NCBI chr 9:94,189,961...94,193,054
Ensembl chr 9:94,190,067...94,192,813
|
|
G |
Angptl4 |
angiopoietin-like 4 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ANGPTL4 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 7:18,627,814...18,634,043
Ensembl chr 7:18,627,808...18,634,079
|
|
G |
Ank2 |
ankyrin 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ANK2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:231,224,643...231,522,655
Ensembl chr 2:231,226,949...231,648,122
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions increases expression |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA]; N-(2-aminoethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA] |
CTD |
PMID:12542607 |
|
NCBI chr 5:57,423,735...57,429,252
Ensembl chr 5:57,423,734...57,429,245
|
|
G |
Aqp5 |
aquaporin 5 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [Cyclic AMP results in decreased expression of AQP5 protein]; Cyclic AMP affects the expression of and results in increased phosphorylation of and results in increased localization of AQP5 protein |
CTD |
PMID:15536076 |
|
NCBI chr 7:141,249,044...141,252,576
Ensembl chr 7:141,249,044...141,252,578
|
|
G |
Armh4 |
armadillo-like helical domain containing 4 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ARMH4 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr15:26,586,359...26,687,412
Ensembl chr15:26,587,179...26,678,420
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
EXP |
Cyclic AMP inhibits the reaction [AHR protein binds to ARNT protein] |
CTD |
PMID:12859982 |
|
NCBI chr 2:196,594,178...196,651,486
Ensembl chr 2:196,594,303...196,651,179
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
[[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein |
CTD |
PMID:25191754 |
|
NCBI chr10:57,040,252...57,048,045
Ensembl chr10:57,040,267...57,048,134
|
|
G |
Atf5 |
activating transcription factor 5 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ATF5 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:100,807,821...100,812,410
Ensembl chr 1:100,808,241...100,810,522
|
|
G |
Avp |
arginine vasopressin |
multiple interactions |
ISO |
[AVP protein binds to and results in increased activity of AVPR2 protein mutant form] which results in increased abundance of Cyclic AMP; [AVP protein binds to and results in increased activity of AVPR2 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:20683494 |
|
NCBI chr 3:123,117,482...123,119,460
Ensembl chr 3:123,117,492...123,119,460
|
|
G |
Avpr2 |
arginine vasopressin receptor 2 |
multiple interactions |
ISO |
[AVP protein binds to and results in increased activity of AVPR2 protein mutant form] which results in increased abundance of Cyclic AMP; [AVP protein binds to and results in increased activity of AVPR2 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:20683494 |
|
NCBI chr X:156,889,006...156,892,707
Ensembl chr X:156,889,410...156,891,213
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
increases activity multiple interactions |
ISO EXP |
Cyclic AMP results in increased activity of BRAF protein [Pentoxifylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein; [Theophylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein |
CTD |
PMID:21693435 |
|
NCBI chr 4:67,389,331...67,520,549
Ensembl chr 4:67,396,192...67,520,356
|
|
G |
C1qtnf5 |
C1q and TNF related 5 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of C1QTNF5 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 8:48,443,515...48,445,639
Ensembl chr 8:48,443,767...48,445,637
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
increases abundance multiple interactions |
ISO EXP |
CALCA protein modified form results in increased abundance of Cyclic AMP; CALCA protein results in increased abundance of Cyclic AMP CALCA protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]] Isoflurane inhibits the reaction [CALCA protein modified form results in increased abundance of Cyclic AMP]; sevoflurane inhibits the reaction [CALCA protein modified form results in increased abundance of Cyclic AMP] |
CTD |
PMID:15297469 PMID:17295025 PMID:17306419 PMID:18463244 |
|
NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
|
|
G |
Carm1 |
coactivator-associated arginine methyltransferase 1 |
multiple interactions increases phosphorylation |
ISO |
[Cyclic AMP results in increased phosphorylation of CARM1 protein] promotes the reaction [CARM1 protein binds to ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased expression of TFF1 mRNA]; Cyclic AMP promotes the reaction [CARM1 protein binds to ESR1 protein]; Cyclic AMP promotes the reaction [CARM1 protein binds to TFF1 promoter] |
CTD |
PMID:20360387 |
|
NCBI chr 8:22,577,723...22,622,555
Ensembl chr 8:22,577,715...22,622,560
|
|
G |
Cckbr |
cholecystokinin B receptor |
multiple interactions |
ISO |
CCKBR protein affects the reaction [[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP] |
CTD |
PMID:11880531 |
|
NCBI chr 1:170,262,218...170,272,298
Ensembl chr 1:170,262,156...170,272,298
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Cyclic AMP inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein] |
CTD |
PMID:9863660 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CCN2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
EXP ISO |
[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein; sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein] |
CTD |
PMID:21693435 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cd3e |
CD3e molecule |
decreases phosphorylation |
ISO |
Cyclic AMP results in decreased phosphorylation of CD3E protein |
CTD |
PMID:2824607 |
|
NCBI chr 8:49,297,604...49,309,370
Ensembl chr 8:49,297,608...49,308,806
|
|
G |
Cd3g |
CD3g molecule |
decreases phosphorylation |
ISO |
Cyclic AMP results in decreased phosphorylation of CD3G protein |
CTD |
PMID:2824607 |
|
NCBI chr 8:49,274,553...49,280,943
Ensembl chr 8:49,274,960...49,280,901
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
EXP ISO |
[Pentoxifylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein; [Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein; Sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein] |
CTD |
PMID:21693435 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases response to substance |
ISO |
CEBPB protein results in increased susceptibility to Cyclic AMP |
CTD |
PMID:23097472 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions increases activity |
ISO EXP |
Cyclic AMP promotes the reaction [CFTR protein results in increased transport of Bicarbonates]; Cyclic AMP promotes the reaction [CFTR protein results in increased transport of Chlorides] CFTR protein promotes the reaction [Cyclic AMP results in increased transport of Chlorine]; Cyclic AMP affects the localization of and results in increased activity of CFTR protein; Nitric Oxide inhibits the reaction [CFTR protein promotes the reaction [Cyclic AMP results in increased transport of Chlorine]]; Nocodazole inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein]; Primaquine inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein] Cyclic AMP results in increased activity of CFTR protein Genistein promotes the reaction [Cyclic AMP results in increased activity of CFTR protein mutant form] |
CTD |
PMID:11786964 PMID:12529251 PMID:12556293 PMID:12612912 PMID:15229107 PMID:15371258 |
|
NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
multiple interactions affects secretion increases abundance |
EXP ISO |
[Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of CGA mRNA CGA protein affects the secretion of Cyclic AMP CGA protein results in increased abundance of Cyclic AMP [CGA protein affects the secretion of Cyclic AMP] which results in increased secretion of Progesterone; [CGA protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Cyclic AMP; [CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Colforsin promotes the reaction [CGA protein results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP] [ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]; ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:8404651 PMID:20378682 PMID:21642635 PMID:23071612 PMID:26895433 PMID:31132478 |
|
NCBI chr 5:50,362,491...50,393,368
Ensembl chr 5:50,381,244...50,393,367
|
|
G |
Chsy1 |
chondroitin sulfate synthase 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CHSY1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:127,010,587...127,071,570
Ensembl chr 1:127,010,588...127,071,570
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
EXP ISO |
[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP; rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:10422789 PMID:11730719 PMID:17953657 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions |
ISO |
[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Pertussis Toxin inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:17558435 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Cp |
ceruloplasmin |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CP mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:104,744,249...104,803,034
Ensembl chr 2:104,744,461...104,799,853
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
[Dexamethasone co-treated with Cyclic AMP] results in increased phosphorylation of CREB1 protein; [Glucagon co-treated with Cyclic AMP] results in increased phosphorylation of CREB1 protein; Cyclic AMP promotes the reaction [CREB1 protein binds to CYP1B1 enhancer] |
CTD |
PMID:12859982 PMID:22676303 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
ISO |
CREBBP protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein] |
CTD |
PMID:20360387 |
|
NCBI chr10:11,590,994...11,721,039
Ensembl chr10:11,595,044...11,721,039
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
ISO EXP |
[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP; Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP] CRH protein inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Cholera Toxin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Manganese results in increased chemical synthesis of Cyclic AMP]; Sphingosine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]] |
CTD |
PMID:2153673 PMID:20702571 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
multiple interactions |
ISO |
[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP; Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:20702571 |
|
NCBI chr10:92,191,473...92,233,662
Ensembl chr10:92,191,718...92,232,645
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
ISO |
Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of CRP mRNA] |
CTD |
PMID:22117073 |
|
NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
|
|
G |
Csf3 |
colony stimulating factor 3 |
increases expression |
ISO |
Cyclic AMP results in increased expression of CSF3 protein |
CTD |
PMID:7540958 |
|
NCBI chr10:86,616,785...86,619,160
Ensembl chr10:86,616,785...86,619,157
|
|
G |
Csk |
C-terminal Src kinase |
multiple interactions |
ISO |
CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]; CSK protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP]; CSK protein promotes the reaction [Terbutaline results in increased abundance of Cyclic AMP]; Isoproterenol inhibits the reaction [CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]] |
CTD |
PMID:1699227 |
|
NCBI chr 8:62,405,714...62,424,707
Ensembl chr 8:62,405,715...62,424,303
|
|
G |
Cstb |
cystatin B |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CSTB mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr20:10,966,357...10,968,399
Ensembl chr20:10,966,331...10,968,432
|
|
G |
Ctsa |
cathepsin A |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CTSA mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 3:161,298,750...161,304,627
Ensembl chr 3:161,298,962...161,304,625
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO |
Cyclic AMP results in increased expression of CYP11A1 mRNA Cyclic AMP results in increased expression of CYP11A1 mRNA; Cyclic AMP results in increased expression of CYP11A1 protein myricetin promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA] |
CTD |
PMID:25576683 PMID:28668616 PMID:29228121 |
|
NCBI chr 8:62,798,317...62,809,848
Ensembl chr 8:62,779,875...62,809,893
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
multiple interactions increases expression |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of CYP11B1 mRNA] |
CTD |
PMID:22172629 |
|
NCBI chr 7:116,248,759...116,255,205
Ensembl chr 7:116,156,219...116,255,167
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
[acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in decreased activity of CYP17A1 protein; [acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in increased activity of CYP17A1 protein; [galaxolide co-treated with Cyclic AMP] results in decreased activity of CYP17A1 protein; [galaxolide co-treated with Cyclic AMP] results in increased activity of CYP17A1 protein Cyclic AMP results in increased expression of CYP17A1 mRNA |
CTD |
PMID:23084589 PMID:25576683 |
|
NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO |
Cyclic AMP results in increased expression of CYP19A1 mRNA; Cyclic AMP results in increased expression of CYP19A1 protein [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA] |
CTD |
PMID:29228121 PMID:31953017 |
|
NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression multiple interactions |
ISO EXP |
Cyclic AMP results in increased expression of CYP1B1 mRNA; Cyclic AMP results in increased expression of CYP1B1 protein AHR protein promotes the reaction [Cyclic AMP results in increased expression of CYP1B1 mRNA]; Cyclic AMP promotes the reaction [AHR protein binds to CYP1B1 enhancer]; Cyclic AMP promotes the reaction [CREB1 protein binds to CYP1B1 enhancer] |
CTD |
PMID:12859982 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
multiple interactions increases expression |
ISO |
Cyclic AMP promotes the reaction [HNF4A protein binds to CYP2A5 promoter]; Cyclic AMP promotes the reaction [PPARGC1A protein binds to CYP2A5 promoter]; Dactinomycin inhibits the reaction [Cyclic AMP results in increased expression of CYP2A5 mRNA] |
CTD |
PMID:12754101 PMID:18602936 |
|
NCBI chr 1:83,653,248...83,662,118
Ensembl chr 1:83,653,234...83,766,484
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
ISO |
Cyclic AMP results in increased expression of CYP51 mRNA |
CTD |
PMID:25576683 |
|
NCBI chr 4:27,175,564...27,194,018
Ensembl chr 4:27,175,243...27,194,018
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
decreases expression decreases activity |
EXP |
Cyclic AMP results in decreased expression of CYP7B1 mRNA Cyclic AMP results in decreased activity of CYP7B1 protein |
CTD |
PMID:12029625 |
|
NCBI chr 2:102,701,903...102,871,257
Ensembl chr 2:102,701,903...102,871,257
|
|
G |
Dap |
death-associated protein |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of DAP mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:84,275,884...84,328,998
Ensembl chr 2:84,275,884...84,328,998
|
|
G |
Ddt |
D-dopachrome tautomerase |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of DDT mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr20:13,827,153...13,829,624
Ensembl chr20:13,827,132...13,831,588
|
|
G |
Disc1 |
DISC1 scaffold protein |
multiple interactions |
ISO |
Cyclic AMP inhibits the reaction [DISC1 protein binds to PDE4B protein] |
CTD |
PMID:16293762 |
|
NCBI chr19:57,818,838...58,069,992
Ensembl chr19:57,820,260...58,066,152
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
affects response to substance |
ISO |
DKK1 protein affects the susceptibility to Cyclic AMP |
CTD |
PMID:21546446 |
|
NCBI chr 1:248,952,896...248,956,579
Ensembl chr 1:248,895,738...248,898,607
|
|
G |
Dld |
dihydrolipoamide dehydrogenase |
increases abundance |
EXP |
DLD protein results in increased abundance of Cyclic AMP |
CTD |
PMID:25981801 |
|
NCBI chr 6:50,597,677...50,618,694
Ensembl chr 6:50,597,677...50,618,694
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
ISO EXP |
A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP] [SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP; A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]; SCH 23390 inhibits the reaction [A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]]; SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]]; Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]; Spiperone inhibits the reaction [A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]] |
CTD |
PMID:8558425 PMID:15711596 |
|
NCBI chr17:11,099,736...11,104,352
Ensembl chr17:11,101,306...11,103,541
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
ISO |
[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; epigallocatechin gallate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] [quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP; CCKBR protein affects the reaction [[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP] |
CTD |
PMID:11880531 PMID:17958328 |
|
NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
|
|
G |
Drd4 |
dopamine receptor D4 |
multiple interactions |
ISO |
[3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine binds to and results in decreased activity of DRD4 protein] inhibits the reaction [Naloxone results in increased abundance of Cyclic AMP] |
CTD |
PMID:15542745 |
|
NCBI chr 1:214,278,296...214,282,818
Ensembl chr 1:214,278,296...214,281,483
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[Cimetidine results in decreased abundance of Cyclic AMP] inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:17295779 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
[[Eugenol results in increased activity of OLFR73 protein] which results in increased abundance of Cyclic AMP] which results in increased expression of EGR1 mRNA |
CTD |
PMID:12767924 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Ehd2 |
EH-domain containing 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of EHD2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:77,847,599...77,865,870
Ensembl chr 1:77,847,600...77,865,870
|
|
G |
Endod1 |
endonuclease domain containing 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ENDOD1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 8:12,898,430...12,928,156
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ENO2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
|
|
G |
Epo |
erythropoietin |
increases expression |
EXP |
Cyclic AMP results in increased expression of EPO protein |
CTD |
PMID:18621143 |
|
NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
|
|
G |
Errfi1 |
ERBB receptor feedback inhibitor 1 |
increases expression |
EXP |
Cyclic AMP results in increased expression of ERRFI1 mRNA |
CTD |
PMID:1472065 |
|
NCBI chr 5:167,951,564...167,966,011
Ensembl chr 5:167,952,728...167,966,009
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases activity |
ISO |
[Cyclic AMP results in increased phosphorylation of CARM1 protein] promotes the reaction [CARM1 protein binds to ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; CREBBP protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; Cyclic AMP promotes the reaction [CARM1 protein binds to ESR1 protein]; ESR1 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased activity of ESR1 protein] |
CTD |
PMID:19766106 PMID:20360387 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
ESR2 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP] [ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]; ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:19766106 PMID:20378682 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
multiple interactions |
ISO |
[C186 65 binds to and results in increased activity of F2R protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [C186 65 binds to and results in increased activity of F2R protein] which results in decreased chemical synthesis of Cyclic AMP |
CTD |
PMID:22207716 |
|
NCBI chr 2:26,118,760...26,135,340
Ensembl chr 2:26,118,760...26,135,340
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
multiple interactions |
ISO |
Cyclic AMP promotes the reaction [F2RL1 protein results in increased transport of Chlorides] |
CTD |
PMID:11804840 |
|
NCBI chr 2:25,222,324...25,235,275
Ensembl chr 2:25,222,328...25,235,275
|
|
G |
F2rl3 |
F2R like thrombin or trypsin receptor 3 |
multiple interactions |
ISO |
[GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] which results in decreased chemical synthesis of Cyclic AMP |
CTD |
PMID:22207716 |
|
NCBI chr16:18,817,797...18,819,790
Ensembl chr16:18,814,622...18,819,833
|
|
G |
Fam20c |
FAM20C, golgi associated secretory pathway kinase |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FAM20C mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr12:17,913,771...17,972,733
Ensembl chr12:17,913,767...17,972,737
|
|
G |
Fcgr2a |
Fc fragment of IgG receptor IIa |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FCGR3 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr13:91,146,878...91,163,691
Ensembl chr13:91,168,973...91,198,036 Ensembl chr13:91,168,973...91,198,036
|
|
G |
Fdx1 |
ferredoxin 1 |
multiple interactions increases expression |
ISO |
myricetin promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA] |
CTD |
PMID:28668616 |
|
NCBI chr 8:56,373,729...56,393,199
Ensembl chr 8:56,373,723...56,393,233
|
|
G |
Fig4 |
FIG4 phosphoinositide 5-phosphatase |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FIG4 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr20:45,922,806...46,044,754
Ensembl chr20:45,922,806...46,044,738
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
[Etoposide co-treated with Cyclic AMP] results in increased expression of FOS mRNA Cyclic AMP results in increased expression of FOS mRNA |
CTD |
PMID:10064622 PMID:10711420 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA] FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]] |
CTD |
PMID:26847930 PMID:31953017 |
|
NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions increases abundance increases secretion |
EXP ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; [Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of FSHB mRNA; fulvestrant inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; Methoxychlor inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP] FSHB protein results in increased secretion of Cyclic AMP NOG protein inhibits the reaction [Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]] [FSHB protein co-treated with Testosterone] results in increased chemical synthesis of Cyclic AMP; [FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Benzo(a)pyrene inhibits the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; Dichlorodiphenyl Dichloroethylene promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; o,p'-DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:8404651 PMID:18535249 PMID:23137853 PMID:23583632 PMID:25549949 PMID:26895433 |
|
NCBI chr 3:98,088,321...98,092,131
Ensembl chr 3:98,088,324...98,092,131
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
ISO |
[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; [FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Benzo(a)pyrene inhibits the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; Dichlorodiphenyl Dichloroethylene promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; o,p'-DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:26895433 |
|
NCBI chr 6:12,796,383...12,997,817
Ensembl chr 6:12,796,383...12,997,817
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
EXP ISO |
[Dexamethasone co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA] [Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein] |
CTD |
PMID:22676303 PMID:26847930 |
|
NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
|
|
G |
Gabpb1 |
GA binding protein transcription factor subunit beta 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GABPB1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 3:119,091,739...119,135,391
Ensembl chr 3:119,091,744...119,135,391
|
|
G |
Gbp2 |
guanylate binding protein 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GBP2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:248,276,795...248,293,784
Ensembl chr 2:248,276,709...248,293,784
|
|
G |
Gcg |
glucagon |
multiple interactions increases chemical synthesis increases abundance |
ISO EXP |
[GCG protein modified form binds to and results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP GCG protein results in increased chemical synthesis of Cyclic AMP Dietary Fats promotes the reaction [GCG protein results in increased chemical synthesis of Cyclic AMP]; Niclosamide inhibits the reaction [GCG protein results in increased abundance of Cyclic AMP] [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein; [GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP |
CTD |
PMID:6312992 PMID:18669601 PMID:20074626 PMID:25191754 PMID:26964897 |
|
NCBI chr 3:48,442,635...48,451,650
Ensembl chr 3:48,442,635...48,451,650
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions |
ISO |
3,9-bis((ethylthio)methyl)-K-252a inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium]; [GDNF protein co-treated with Cyclic AMP] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; [GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium; Mazindol inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium]; vanoxerine inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:19647008 |
|
NCBI chr 2:56,884,181...56,912,964
Ensembl chr 2:56,887,987...56,910,238
|
|
G |
Ghrh |
growth hormone releasing hormone |
multiple interactions |
ISO |
[GH-RH(1-29), desaminotyrosyl(1)-ornithyl(12,21)-alpha-aminobutryic acid(15)-norleucyl(27)-aspartyl(28)-agmatine(29)- binds to and results in increased activity of GHRH protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:22308467 |
|
NCBI chr 3:153,449,124...153,468,794
Ensembl chr 3:153,449,125...153,468,794
|
|
G |
Gip |
gastric inhibitory polypeptide |
multiple interactions |
ISO |
[GIP protein binds to and results in increased activity of GIPR protein] which results in increased chemical synthesis of Cyclic AMP |
CTD |
PMID:25191754 |
|
NCBI chr10:83,835,080...83,848,399
Ensembl chr10:83,840,303...83,848,396
|
|
G |
Gipr |
gastric inhibitory polypeptide receptor |
multiple interactions |
ISO |
[GIP protein binds to and results in increased activity of GIPR protein] which results in increased chemical synthesis of Cyclic AMP |
CTD |
PMID:25191754 |
|
NCBI chr 1:80,063,047...80,073,223
Ensembl chr 1:80,063,049...80,073,223
|
|
G |
Glipr2 |
GLI pathogenesis-related 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GLIPR2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 5:59,415,415...59,446,732
Ensembl chr 5:59,416,076...59,446,647
|
|
G |
Glp1r |
glucagon-like peptide 1 receptor |
multiple interactions |
ISO |
[GCG protein modified form binds to and results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein; [GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP |
CTD |
PMID:18669601 PMID:25191754 |
|
NCBI chr20:9,586,075...9,626,228
Ensembl chr20:9,586,075...9,626,228
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
multiple interactions |
ISO |
[[IER3 protein affects the chemical synthesis of Reactive Oxygen Species] which results in increased expression of GNAI2] which results in decreased chemical synthesis of Cyclic AMP |
CTD |
PMID:20713914 |
|
NCBI chr 8:116,370,730...116,391,337
Ensembl chr 8:116,370,744...116,391,307
|
|
G |
Gnal |
G protein subunit alpha L |
multiple interactions |
ISO |
[[GNAL protein results in increased susceptibility to citronellal] which results in increased activity of OLFR49 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:15598656 |
|
NCBI chr18:62,805,406...62,946,133
Ensembl chr18:62,805,410...62,944,630
|
|
G |
Gnas |
GNAS complex locus |
multiple interactions |
ISO |
[[GNAS protein results in increased susceptibility to citronellal] which results in increased activity of OLFR49 protein] which results in increased abundance of Cyclic AMP; GNAS protein promotes the reaction [[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP] [[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:11895442 PMID:15598656 PMID:23022524 |
|
NCBI chr 3:172,374,957...172,434,988
Ensembl chr 3:172,374,957...172,428,483 Ensembl chr 3:172,374,957...172,428,483
|
|
G |
Gpbar1 |
G protein-coupled bile acid receptor 1 |
multiple interactions |
ISO |
[[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP [Chenodeoxycholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; [Colforsin binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; [Lithocholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:17963371 PMID:23022524 |
|
NCBI chr 9:81,555,914...81,560,931
Ensembl chr 9:81,559,605...81,560,594
|
|
G |
Gpc3 |
glypican 3 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GPC3 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr X:139,579,268...139,947,093
Ensembl chr X:139,579,268...139,916,883
|
|
G |
Greb1l |
GREB1 like retinoic acid receptor coactivator |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GREB1L mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr18:1,537,315...1,784,260
Ensembl chr18:1,723,565...1,784,233
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
multiple interactions |
ISO |
[[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein] |
CTD |
PMID:25191754 |
|
NCBI chr 1:219,536,220...219,544,329
Ensembl chr 1:219,536,220...219,544,328
|
|
G |
Grn |
granulin precursor |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GRN mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr10:90,377,103...90,383,207
Ensembl chr10:90,376,933...90,383,205
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
GSK3B protein affects the reaction [Deamino Arginine Vasopressin results in increased abundance of Cyclic AMP] |
CTD |
PMID:20056751 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Gtpbp2 |
GTP binding protein 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GTPBP2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 9:17,198,957...17,208,456
Ensembl chr 9:17,198,957...17,209,220
|
|
G |
Gypc |
glycophorin C (Gerbich blood group) |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GYPC mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr18:25,312,386...25,344,614
Ensembl chr18:25,312,387...25,344,614
|
|
G |
Hcar2 |
hydroxycarboxylic acid receptor 2 |
multiple interactions decreases abundance |
ISO |
[3-Hydroxybutyric Acid results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Niacin results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Pertussis Toxin inhibits the reaction [[Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] [HCAR2 protein results in decreased abundance of Cyclic AMP] which results in decreased expression of ABCA1 protein; [Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased abundance of Cyclic AMP |
CTD |
PMID:12563315 PMID:17124637 PMID:19223991 PMID:20655299 |
|
NCBI chr12:38,160,464...38,161,546
Ensembl chr12:38,160,464...38,161,546
|
|
G |
Hdac2 |
histone deacetylase 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HDAC2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr20:43,084,870...43,108,198
Ensembl chr20:43,084,870...43,108,198
|
|
G |
Hdac6 |
histone deacetylase 6 |
affects abundance |
ISO |
HDAC6 protein affects the abundance of Cyclic AMP |
CTD |
PMID:28887310 |
|
NCBI chr X:15,295,372...15,316,673
Ensembl chr X:15,295,473...15,316,671
|
|
G |
Hist2h2be |
histone cluster 2 H2B family member E |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HIST2H2BE mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:198,360,837...198,363,399
Ensembl chr 2:198,360,998...198,361,378
|
|
G |
Hivep2 |
HIVEP zinc finger 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HIVEP2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:8,129,354...8,333,890
Ensembl chr 1:8,310,577...8,333,885
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
multiple interactions |
ISO |
Cyclic AMP promotes the reaction [HNF4A protein binds to CYP2A5 promoter] |
CTD |
PMID:18602936 |
|
NCBI chr 3:159,902,441...159,965,003
Ensembl chr 3:159,902,441...159,965,003
|
|
G |
Hp |
haptoglobin |
multiple interactions |
ISO |
Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of HP mRNA] |
CTD |
PMID:22117073 |
|
NCBI chr19:42,096,255...42,100,805
Ensembl chr19:42,097,995...42,100,804
|
|
G |
Hrh1 |
histamine receptor H 1 |
multiple interactions |
ISO |
1-Methyl-3-isobutylxanthine inhibits the reaction [HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]]; HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]; Triprolidine inhibits the reaction [HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]] |
CTD |
PMID:2419744 |
|
NCBI chr 4:146,374,596...146,458,148
Ensembl chr 4:146,455,332...146,457,074
|
|
G |
Hrh2 |
histamine receptor H 2 |
increases abundance multiple interactions |
ISO |
HRH2 protein results in increased abundance of Cyclic AMP [Cimetidine binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cyclic AMP; [Dimaprit binds to and results in increased activity of HRH2 protein] which results in increased abundance of Cyclic AMP; [Histamine binds to and results in increased activity of HRH2 protein] which results in increased abundance of Cyclic AMP; Burimamide inhibits the reaction [[Cyclic AMP binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cimetidine]; Burimamide inhibits the reaction [[Cyclic AMP binds to and results in increased activity of HRH2 protein] which results in increased abundance of Histamine]; Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12A protein]; Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12B protein]; Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP]]; HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]; HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP] |
CTD |
PMID:9187264 PMID:9681472 PMID:15843518 |
|
NCBI chr17:10,912,959...10,931,389
Ensembl chr17:10,921,507...10,952,441
|
|
G |
Hrh3 |
histamine receptor H3 |
multiple interactions |
EXP |
[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; ciproxifan inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; thioperamide inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:21276809 |
|
NCBI chr 3:175,474,310...175,479,395
Ensembl chr 3:175,473,078...175,479,395
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
increases expression |
ISO |
Cyclic AMP results in increased expression of HSD3B1 mRNA |
CTD |
PMID:25576683 |
|
|
|
G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
increases expression |
ISO |
Cyclic AMP results in increased expression of HSD3B2 mRNA |
CTD |
PMID:18490834 |
|
NCBI chr 2:200,712,895...200,722,429
Ensembl chr 2:202,341,422...202,350,929
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
ISO |
[JB-788 binds to and results in increased activity of HTR1A protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Arachidonic Acid metabolite inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Melitten inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:11356925 PMID:20580787 |
|
NCBI chr 2:36,246,628...36,247,896
Ensembl chr 2:36,246,628...36,247,896
|
|
G |
Htr1b |
5-hydroxytryptamine receptor 1B |
multiple interactions |
ISO |
HTR1B affects the reaction [almotriptan inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:11134654 |
|
NCBI chr 8:89,113,984...89,130,830
Ensembl chr 8:89,129,453...89,130,991
|
|
G |
Htr6 |
5-hydroxytryptamine receptor 6 |
increases abundance multiple interactions |
ISO |
HTR6 protein results in increased abundance of Cyclic AMP Serotonin promotes the reaction [HTR6 protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:11406289 |
|
NCBI chr 5:157,501,202...157,518,870
Ensembl chr 5:157,503,040...157,518,631
|
|
G |
Htr7 |
5-hydroxytryptamine receptor 7 |
increases abundance multiple interactions |
ISO |
HTR7 results in increased abundance of Cyclic AMP [3,N-dimethyl-N-(1-methyl-3-(4-methylpiperidin-1-yl)propyl)benzenesulfonamide binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [5-carboxamidotryptamine binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [5-Methoxytryptamine binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Bromocriptine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Clozapine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Ketanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Lisuride binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [mesulergine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] which results in decreased abundance of Cyclic AMP; [Methoxydimethyltryptamines binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Mianserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Risperidone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Ritanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Serotonin binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Spiperone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [volinanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP] |
CTD |
PMID:10720076 PMID:14578406 PMID:19509219 |
|
NCBI chr 1:254,547,964...254,671,811
Ensembl chr 1:254,547,620...254,671,778
|
|
G |
Htra1 |
HtrA serine peptidase 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HTRA1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:201,499,067...201,548,508
Ensembl chr 1:201,499,028...201,548,513
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Cyclic AMP] |
CTD |
PMID:27469509 |
|
NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
|
|
G |
Ier3 |
immediate early response 3 |
multiple interactions affects response to substance |
EXP ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IER3 mRNA] IER3 protein affects the susceptibility to Cyclic AMP [[IER3 protein affects the chemical synthesis of Reactive Oxygen Species] which results in increased expression of GNAI2] which results in decreased chemical synthesis of Cyclic AMP; IER3 protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP]; Pertussis Toxin affects the reaction [IER3 protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP]] |
CTD |
PMID:19414516 PMID:20713914 |
|
NCBI chr20:3,438,798...3,440,002
Ensembl chr20:3,438,798...3,440,769
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA] |
CTD |
PMID:31953017 |
|
NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IGFBP5 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 9:80,154,230...80,166,813
Ensembl chr 9:80,150,211...80,167,033
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12A protein] |
CTD |
PMID:15843518 |
|
NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12B protein] |
CTD |
PMID:15843518 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il15ra |
interleukin 15 receptor subunit alpha |
multiple interactions decreases expression |
ISO |
[Metformin co-treated with Cyclic AMP] results in decreased expression of IL15RA mRNA; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in decreased expression of IL15RA mRNA] |
CTD |
PMID:22117073 |
|
NCBI chr17:70,451,861...70,481,838
Ensembl chr17:70,451,411...70,481,750
|
|
G |
Il17re |
interleukin 17 receptor E |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IL17RE mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 4:145,413,157...145,426,608
Ensembl chr 4:145,413,230...145,426,603
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases abundance |
ISO |
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]; Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]; Ibuprofen inhibits the reaction [IL1B protein results in increased abundance of Cyclic AMP]; KT 5720 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]; KT 5823 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]; Rolipram promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP] Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of CRP mRNA]; Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of HP mRNA]; Cyclic AMP promotes the reaction [IL1B protein results in increased expression of IL1RN mRNA] |
CTD |
PMID:8904084 PMID:17709599 PMID:22117073 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
multiple interactions increases expression |
ISO |
Cyclic AMP promotes the reaction [IL1B protein results in increased expression of IL1RN mRNA]; Cyclic AMP promotes the reaction [Metformin results in increased expression of IL1RN mRNA]; Metformin promotes the reaction [Cyclic AMP results in increased expression of IL1RN mRNA]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in increased expression of IL1RN mRNA] |
CTD |
PMID:22117073 |
|
NCBI chr 3:1,449,778...1,468,624
Ensembl chr 3:1,452,644...1,468,614
|
|
G |
Il4 |
interleukin 4 |
increases chemical synthesis multiple interactions |
ISO |
IL4 protein results in increased chemical synthesis of Cyclic AMP Ketoconazole inhibits the reaction [IL4 protein results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:12230500 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
increases expression |
EXP |
Cyclic AMP analog results in increased expression of IL6 mRNA |
CTD |
PMID:10469353 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Inhba |
inhibin subunit beta A |
increases secretion |
ISO |
Cyclic AMP results in increased secretion of INHBA protein |
CTD |
PMID:20074812 |
|
NCBI chr17:51,894,869...51,919,998
Ensembl chr17:51,898,217...51,912,496
|
|
G |
Iqgap1 |
IQ motif containing GTPase activating protein 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IQGAP1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:142,525,041...142,615,673
Ensembl chr 1:142,525,046...142,615,673
|
|
G |
Irf6 |
interferon regulatory factor 6 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IRF6 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr13:111,870,121...111,889,328
Ensembl chr13:111,870,121...111,889,328
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ITGB1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Etoposide co-treated with Cyclic AMP] results in increased expression of JUN mRNA |
CTD |
PMID:10711420 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Kcnd2 |
potassium voltage-gated channel subfamily D member 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of KCND2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 4:48,309,283...48,816,804
|
|
G |
Kif15 |
kinesin family member 15 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of KIF15 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 8:132,033,117...132,103,528
Ensembl chr 8:132,032,944...132,103,927
|
|
G |
Kng2 |
kininogen 2 |
increases abundance |
EXP |
KNG1 results in increased abundance of Cyclic AMP |
CTD |
PMID:15750287 |
|
NCBI chr11:81,509,185...81,516,759
|
|
G |
Lamp1 |
lysosomal-associated membrane protein 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LAMP1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr16:81,689,576...81,714,341
Ensembl chr16:81,689,335...81,714,419
|
|
G |
Lep |
leptin |
increases abundance multiple interactions increases expression |
ISO |
LEP protein results in increased abundance of Cyclic AMP 3-(5-tert-butylisoxazol-3-yl)-2-((3-chlorophenyl)hydrazono)-3-oxopropionitrile inhibits the reaction [Cyclic AMP analog results in increased expression of LEP mRNA] |
CTD |
PMID:11342529 PMID:27381457 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions increases chemical synthesis affects secretion increases abundance |
EXP ISO |
5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]; [Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP; [Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP; [Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of LHB mRNA; [LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP; CRH protein inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]; Masoprocol inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]; Sphingosine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Sphingosine inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Tetradecanoylphorbol Acetate inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP] CGB3 protein results in increased chemical synthesis of Cyclic AMP; LHB protein results in increased chemical synthesis of Cyclic AMP LHB protein affects the secretion of Cyclic AMP [LHB protein affects the secretion of Cyclic AMP] which results in increased secretion of Progesterone; [LHB protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Cyclic AMP |
CTD |
PMID:2153673 PMID:6430271 PMID:8404651 PMID:23071612 |
|
NCBI chr 1:101,409,992...101,413,725
Ensembl chr 1:101,410,019...101,413,724
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
multiple interactions |
ISO |
[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP; ESR1 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; ESR2 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP] [ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:19766106 PMID:20378682 |
|
NCBI chr 6:12,493,182...12,554,482
Ensembl chr 6:12,493,943...12,554,439
|
|
G |
Lipe |
lipase E, hormone sensitive type |
increases activity |
ISO |
Cyclic AMP results in increased activity of LIPE protein |
CTD |
PMID:7155675 |
|
NCBI chr 1:82,248,031...82,266,727
Ensembl chr 1:82,248,046...82,266,727
|
|
G |
Lmna |
lamin A/C |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LMNA mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:187,842,884...187,863,552
Ensembl chr 2:187,842,885...187,863,516
|
|
G |
LOC100912605 |
olfactory receptor 5D14-like |
multiple interactions |
ISO |
[[Eugenol results in increased activity of OLFR73 protein] which results in increased abundance of Cyclic AMP] which results in increased expression of EGR1 mRNA; [Eugenol binds to and results in increased activity of OLFR73 protein] which results in increased abundance of Cyclic AMP; [Eugenol results in increased activity of OLFR73 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:12767924 PMID:15716417 |
|
NCBI chr 3:76,255,179...76,256,129
Ensembl chr 3:76,255,179...76,256,129
|
|
G |
Lurap1l |
leucine rich adaptor protein 1-like |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LURAP1L mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 5:98,468,039...98,515,126
Ensembl chr 5:98,469,047...98,515,125
|
|
G |
Man1a1 |
mannosidase, alpha, class 1A, member 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of MAN1A mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr20:35,257,688...35,450,132
Ensembl chr20:35,257,985...35,450,513
|
|
G |
Mc2r |
melanocortin 2 receptor |
multiple interactions |
ISO |
[acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in decreased expression of MC2R mRNA |
CTD |
PMID:23084589 |
|
NCBI chr18:64,166,959...64,178,729
Ensembl chr18:64,167,191...64,177,729
|
|
G |
Msantd3 |
Myb/SANT DNA binding domain containing 3 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of MSANTD3 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 5:64,282,351...64,308,606
Ensembl chr 5:64,282,351...64,306,860
|
|
G |
Ndufb11 |
NADH:ubiquinone oxidoreductase subunit B11 |
increases phosphorylation multiple interactions |
ISO |
Cyclic AMP results in increased phosphorylation of NDUFB11 protein Zalcitabine inhibits the reaction [Cyclic AMP results in increased phosphorylation of NDUFB11 protein]; Zidovudine inhibits the reaction [Cyclic AMP results in increased phosphorylation of NDUFB11 protein] |
CTD |
PMID:17904600 |
|
NCBI chr X:1,787,266...1,789,524
Ensembl chr X:1,787,266...1,789,524
|
|
G |
Ngf |
nerve growth factor |
multiple interactions increases expression |
EXP |
[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA; [Isoproterenol results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA Cyclic AMP results in increased expression of NGF mRNA |
CTD |
PMID:2174743 PMID:2853697 |
|
NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
|
|
G |
Nog |
noggin |
multiple interactions |
ISO |
NOG protein inhibits the reaction [Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]] |
CTD |
PMID:23137853 |
|
NCBI chr10:76,811,759...76,813,386
Ensembl chr10:76,811,759...76,813,386
|
|
G |
Npl |
N-acetylneuraminate pyruvate lyase |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of NPL mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr13:70,938,073...70,981,179
Ensembl chr13:70,938,082...70,980,913
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
decreases expression multiple interactions |
ISO |
Cyclic AMP results in decreased expression of NR0B1 mRNA Verapamil promotes the reaction [Cyclic AMP results in decreased expression of NR0B1 mRNA] |
CTD |
PMID:19822634 |
|
NCBI chr X:54,734,385...54,738,513
Ensembl chr X:54,734,385...54,738,513
|
|
G |
Ntan1 |
N-terminal asparagine amidase |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of NTAN1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr10:3,218,414...3,235,229
|
|
G |
Oat |
ornithine aminotransferase |
increases activity multiple interactions increases expression |
EXP |
Cyclic AMP results in increased activity of OAT protein Deoxyglucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Dihydroxyacetone inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Fructose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Fructose inhibits the reaction [Cyclic AMP results in increased expression of OAT mRNA]; Galactose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Glucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Glycerol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Inositol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Mannitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Mannose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Rhamnose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Ribose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Sorbitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Sorbose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Xylitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein] |
CTD |
PMID:2824512 PMID:2827574 |
|
NCBI chr 1:204,562,289...204,582,070
Ensembl chr 1:204,562,289...204,582,070
|
|
G |
Olr72 |
olfactory receptor 72 |
multiple interactions |
ISO |
[pelargonic acid results in increased activity of OLFR586 protein] which results in increased abundance of Cyclic AMP; octanoic acid promotes the reaction [[pelargonic acid results in increased activity of OLFR586 protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:15598656 |
|
NCBI chr 1:168,176,132...168,177,139
Ensembl chr 1:168,176,132...168,177,139
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
multiple interactions |
ISO |
[7-benzylidenenaltrexone binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [[Naloxone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; [[Naltrexone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; [chlornaltrexamine binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [clocinnamox binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [nalmefene binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP |
CTD |
PMID:11413242 |
|
NCBI chr 1:43,454,803...43,704,948
Ensembl chr 1:43,454,803...43,704,948
|
|
G |
Os9 |
OS9, endoplasmic reticulum lectin |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of OS9 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 7:70,378,625...70,407,135
Ensembl chr 7:70,380,311...70,407,177
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression multiple interactions |
EXP ISO |
Cyclic AMP results in increased expression of PCK1 mRNA [Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein] [Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; Hydrogen Peroxide inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; ochratoxin A inhibits the reaction [Cyclic AMP results in increased expression of PCK1 mRNA]; sodium arsenite inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA] |
CTD |
PMID:2569870 PMID:8971075 PMID:10446394 PMID:22117073 PMID:22676303 PMID:26847930 |
|
NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
|
|
G |
Pde10a |
phosphodiesterase 10A |
multiple interactions increases hydrolysis |
ISO |
Cyclic AMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]; Cyclic GMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP] |
CTD |
PMID:10373451 |
|
NCBI chr 1:52,360,296...52,544,448
Ensembl chr 1:52,360,296...52,544,450
|
|
G |
Pde11a |
phosphodiesterase 11A |
increases hydrolysis |
ISO |
PDE11A protein results in increased hydrolysis of Cyclic AMP |
CTD |
PMID:10725373 |
|
NCBI chr 3:62,818,502...63,211,843
Ensembl chr 3:62,818,502...63,211,845
|
|
G |
Pde4b |
phosphodiesterase 4B |
multiple interactions |
ISO |
[[S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; [S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP [Bresol results in decreased activity of PDE4B protein] which results in increased abundance of Cyclic AMP; Cyclic AMP inhibits the reaction [DISC1 protein binds to PDE4B protein] |
CTD |
PMID:16293762 PMID:21266552 PMID:21854221 |
|
NCBI chr 5:121,759,236...122,136,814
Ensembl chr 5:121,952,977...122,136,814
|
|
G |
Pde7a |
phosphodiesterase 7A |
multiple interactions increases hydrolysis |
ISO |
1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; Papaverine inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP] |
CTD |
PMID:10618442 PMID:10814504 |
|
NCBI chr 2:104,042,124...104,134,101
Ensembl chr 2:104,045,811...104,134,101
|
|
G |
Pde7b |
phosphodiesterase 7B |
increases hydrolysis multiple interactions |
ISO |
PDE7B protein results in increased hydrolysis of Cyclic AMP 1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; E 4021 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; vinpocetine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP] 1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Papaverine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP] |
CTD |
PMID:10618442 PMID:10814504 PMID:10872825 |
|
NCBI chr 1:15,889,845...16,203,909
Ensembl chr 1:15,893,533...16,203,909
|
|
G |
Pde8a |
phosphodiesterase 8A |
multiple interactions increases metabolic processing increases hydrolysis |
ISO |
Dipyridamole inhibits the reaction [PDE8A protein results in increased metabolism of Cyclic AMP]; E 4021 inhibits the reaction [PDE8A protein results in increased metabolism of Cyclic AMP] PDE8A protein results in increased hydrolysis of Cyclic AMP Dipyridamole inhibits the reaction [PDE8A protein results in increased hydrolysis of Cyclic AMP] |
CTD |
PMID:9671792 PMID:12681444 |
|
NCBI chr 1:143,036,083...143,160,395
Ensembl chr 1:143,036,218...143,159,433
|
|
G |
Pde8b |
phosphodiesterase 8B |
multiple interactions increases metabolic processing increases hydrolysis |
ISO |
9-(2-hydroxy-3-nonyl)adenine inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE8B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; E 4021 inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; Sildenafil Citrate inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP] |
CTD |
PMID:9784418 PMID:12681444 |
|
NCBI chr 2:24,718,548...24,955,533
Ensembl chr 2:24,719,976...24,923,128
|
|
G |
Pde9a |
phosphodiesterase 9A |
increases hydrolysis |
ISO |
PDE9A protein results in increased hydrolysis of Cyclic AMP |
CTD |
PMID:9624146 |
|
NCBI chr20:10,123,624...10,216,325
Ensembl chr20:10,123,651...10,216,548
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions affects abundance |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; [PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; tubacin affects the reaction [[PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP]; tubacin affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; tubastatin A affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; W 7 affects the reaction [PDK1 protein affects the abundance of Cyclic AMP] |
CTD |
PMID:28887310 |
|
NCBI chr 3:58,530,870...58,561,494
Ensembl chr 3:58,530,870...58,558,027
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
multiple interactions |
ISO |
PEBP1 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP] |
CTD |
PMID:26670611 |
|
NCBI chr12:45,026,948...45,031,148
Ensembl chr12:45,026,886...45,031,145
|
|
G |
Pfn2 |
profilin 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of PFN2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:147,953,858...147,959,692
Ensembl chr 2:147,955,196...148,050,438
|
|
G |
Pkia |
cAMP-dependent protein kinase inhibitor alpha |
multiple interactions |
ISO |
[PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PKIA protein] |
CTD |
PMID:29669941 |
|
NCBI chr 2:96,593,185...96,668,222
Ensembl chr 2:96,595,088...96,668,222
|
|
G |
Pla2g4a |
phospholipase A2 group IVA |
increases expression multiple interactions |
EXP |
Cyclic AMP results in increased expression of PLA2G4A mRNA; Cyclic AMP results in increased expression of PLA2G4A protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of PLA2G4A mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of PLA2G4A protein] |
CTD |
PMID:22187434 |
|
NCBI chr13:67,062,252...67,206,688
Ensembl chr13:66,988,937...67,206,693
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions increases abundance |
EXP ISO |
[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP; INS1 protein inhibits the reaction [[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP] POMC protein modified form results in increased abundance of Cyclic AMP Quercetin analog inhibits the reaction [POMC protein modified form results in increased abundance of Cyclic AMP] |
CTD |
PMID:4306506 PMID:26586997 |
|
NCBI chr 6:28,382,937...28,388,771
Ensembl chr 6:28,382,962...28,388,967
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases expression |
ISO |
Cyclic AMP results in increased expression of POR mRNA |
CTD |
PMID:25576683 |
|
NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions increases expression |
ISO EXP |
Cyclic AMP promotes the reaction [PPARGC1A protein binds to CYP2A5 promoter]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in decreased expression of IL15RA mRNA]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in increased expression of IL1RN mRNA] [Dexamethasone co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA]; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased phosphorylation of PPARGC1A protein]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased phosphorylation of PPARGC1A protein] Cyclic AMP results in increased expression of PPARGC1A mRNA |
CTD |
PMID:18602936 PMID:22117073 PMID:22676303 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Ppp1r14b |
protein phosphatase 1, regulatory (inhibitor) subunit 14B |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of PPP1R14B mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:222,229,835...222,231,945
Ensembl chr 1:222,229,835...222,231,944
|
|
G |
Prkacb |
protein kinase cAMP-activated catalytic subunit beta |
multiple interactions affects response to substance |
ISO |
[PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PKIA protein]; [PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein] |
CTD |
PMID:29669941 |
|
NCBI chr 2:252,602,197...252,691,886
Ensembl chr 2:252,605,307...252,691,886
|
|
G |
Prkar1a |
protein kinase cAMP-dependent type I regulatory subunit alpha |
multiple interactions |
ISO |
[PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein] |
CTD |
PMID:29669941 |
|
NCBI chr10:97,940,705...97,959,199
Ensembl chr10:97,940,705...97,957,336
|
|
G |
Prkar2a |
protein kinase cAMP-dependent type II regulatory subunit alpha |
multiple interactions |
EXP |
Clozapine inhibits the reaction [Cyclic AMP binds to PRKAR2A protein]; Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2A protein] |
CTD |
PMID:11907174 |
|
NCBI chr 8:117,486,085...117,548,768
Ensembl chr 8:117,486,083...117,546,370
|
|
G |
Prkar2b |
protein kinase cAMP-dependent type II regulatory subunit beta |
multiple interactions |
EXP |
Clozapine inhibits the reaction [Cyclic AMP binds to PRKAR2B protein]; Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2B protein] |
CTD |
PMID:11907174 |
|
NCBI chr 6:51,265,509...51,356,383
Ensembl chr 6:51,265,515...51,356,383
|
|
G |
Prl |
prolactin |
multiple interactions increases secretion |
EXP ISO |
[Atrazine results in increased abundance of Cyclic AMP] which results in increased secretion of PRL protein [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA] Cyclic AMP results in increased secretion of PRL protein |
CTD |
PMID:20074812 PMID:23022511 PMID:31953017 |
|
NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
|
|
G |
Prok1 |
prokineticin 1 |
affects response to substance |
ISO |
PROK1 protein affects the susceptibility to Cyclic AMP |
CTD |
PMID:21546446 |
|
NCBI chr 2:209,986,503...209,994,438
Ensembl chr 2:209,987,992...209,993,250
|
|
G |
Ptgdr2 |
prostaglandin D2 receptor 2 |
multiple interactions |
ISO |
[5-hydroxyindomethacin binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP; [Indomethacin binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP; [sulindac sulfide binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP |
CTD |
PMID:15563582 |
|
NCBI chr 1:226,976,455...226,995,641
Ensembl chr 1:226,993,250...226,994,849
|
|
G |
Ptger2 |
prostaglandin E receptor 2 |
multiple interactions |
ISO |
[Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:23526216 |
|
NCBI chr15:19,336,029...19,349,759
Ensembl chr15:19,338,175...19,350,210
|
|
G |
Ptger3 |
prostaglandin E receptor 3 |
multiple interactions |
ISO |
[Dinoprostone results in increased activity of PTGER3 protein] which results in decreased abundance of Cyclic AMP |
CTD |
PMID:10357836 |
|
NCBI chr 2:263,895,093...263,979,682
Ensembl chr 2:263,895,241...263,979,698
|
|
G |
Ptger4 |
prostaglandin E receptor 4 |
multiple interactions |
ISO |
[Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:23526216 |
|
NCBI chr 2:54,951,625...54,966,470
Ensembl chr 2:54,952,821...54,963,448
|
|
G |
Ptgir |
prostaglandin I2 receptor |
multiple interactions |
ISO |
[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP; GNAS protein promotes the reaction [[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:11895442 |
|
NCBI chr 1:78,833,449...78,835,832
Ensembl chr 1:78,833,157...78,837,623
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased abundance of Cyclic AMP] |
CTD |
PMID:21873648 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Pth |
parathyroid hormone |
increases abundance |
EXP |
PTH protein results in increased abundance of Cyclic AMP |
CTD |
PMID:26851681 |
|
NCBI chr 1:178,215,829...178,218,761
Ensembl chr 1:178,215,829...178,218,761
|
|
G |
Pthlh |
parathyroid hormone-like hormone |
increases abundance |
ISO |
PTHLH protein results in increased abundance of Cyclic AMP |
CTD |
PMID:10600786 |
|
NCBI chr 4:181,663,425...181,674,181
|
|
G |
Ptma |
prothymosin alpha |
increases abundance |
ISO |
PTMA protein results in increased abundance of Cyclic AMP |
CTD |
PMID:9147362 |
|
NCBI chr 9:93,545,396...93,549,436
Ensembl chr 9:93,545,396...93,549,436
|
|
G |
Rab3b |
RAB3B, member RAS oncogene family |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RAB3B mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 5:128,501,789...128,568,170
Ensembl chr 5:128,501,847...128,568,188
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
increases activity |
ISO |
Cyclic AMP results in increased activity of RAP1A protein |
CTD |
PMID:24701590 |
|
NCBI chr 2:208,193,950...208,215,186
Ensembl chr 2:208,193,954...208,215,187
|
|
G |
Rap1b |
RAP1B, member of RAS oncogene family |
multiple interactions |
EXP ISO |
[Pentoxifylline results in increased abundance of Cyclic AMP] results in increased abundance of [RAP1B protein binds to Guanosine Triphosphate] |
CTD |
PMID:21693435 |
|
NCBI chr 7:60,850,406...60,878,226
Ensembl chr 7:60,853,930...60,860,990
|
|
G |
Rbm12 |
RNA binding motif protein 12 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RBM12 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 3:151,616,038...151,658,427
Ensembl chr 3:151,641,095...151,658,417 Ensembl chr 3:151,641,095...151,658,417 Ensembl chr 3:151,641,095...151,658,417 Ensembl chr 3:151,641,095...151,658,417
|
|
G |
RGD1310587 |
similar to hypothetical protein FLJ14146 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RGD1310587 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr13:102,780,885...102,790,621
Ensembl chr13:102,780,877...102,790,639
|
|
G |
Rgl1 |
ral guanine nucleotide dissociation stimulator,-like 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RGL1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr13:69,909,122...70,174,590
Ensembl chr13:69,909,096...70,174,565
|
|
G |
Rmdn3 |
regulator of microtubule dynamics 3 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RMDN3 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 3:110,943,843...110,964,449
Ensembl chr 3:110,943,826...110,964,452
|
|
G |
Sct |
secretin |
multiple interactions increases abundance |
EXP |
Epinephrine inhibits the reaction [SCT protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:6312992 |
|
NCBI chr 1:214,264,865...214,277,437
Ensembl chr 1:214,264,754...214,265,668
|
|
G |
Sdc1 |
syndecan 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SDC1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 6:33,885,576...33,908,038
Ensembl chr 6:33,885,495...33,908,016
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
affects transport |
ISO |
SLC22A8 protein affects the transport of Cyclic AMP |
CTD |
PMID:11306713 |
|
NCBI chr 1:224,799,444...224,818,482
Ensembl chr 1:224,800,252...224,818,482
|
|
G |
Slc2a5 |
solute carrier family 2 member 5 |
affects expression multiple interactions |
ISO EXP |
Cyclic AMP affects the expression of SLC2A5 mRNA [[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein] which results in increased uptake of Fructose; [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein [Fructose results in increased abundance of Cyclic AMP] which results in increased stability of SLC2A5 mRNA |
CTD |
PMID:8037665 PMID:8554516 PMID:12820898 |
|
NCBI chr 5:167,142,182...167,174,203
Ensembl chr 5:167,141,875...167,174,310
|
|
G |
Slc4a2 |
solute carrier family 4 member 2 |
multiple interactions |
EXP |
Nitric Oxide inhibits the reaction [SLC4A2 protein promotes the reaction [Cyclic AMP results in increased transport of Bicarbonates]]; SLC4A2 protein promotes the reaction [Cyclic AMP results in increased transport of Bicarbonates] |
CTD |
PMID:12612912 |
|
NCBI chr 4:7,264,677...7,282,355
Ensembl chr 4:7,264,683...7,281,223
|
|
G |
Smoc2 |
SPARC related modular calcium binding 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SMOC2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:56,242,289...56,374,106
Ensembl chr 1:56,242,346...56,374,120
|
|
G |
Snx33 |
sorting nexin 33 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SNX33 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 8:61,584,656...61,596,055
Ensembl chr 8:61,584,656...61,595,032
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein]; [[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein; dorsomorphin inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein] |
CTD |
PMID:23782265 |
|
NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA] |
CTD |
PMID:20685861 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Srd5a1 |
steroid 5 alpha-reductase 1 |
increases expression |
ISO |
Cyclic AMP results in increased expression of SRD5A1 mRNA |
CTD |
PMID:25576683 |
|
NCBI chr 1:36,320,504...36,354,694
Ensembl chr 1:36,320,461...36,354,756
|
|
G |
Sst |
somatostatin |
multiple interactions |
ISO |
[SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:22056254 |
|
NCBI chr11:80,358,172...80,359,449
Ensembl chr11:80,358,211...80,359,444
|
|
G |
Sstr2 |
somatostatin receptor 2 |
multiple interactions |
ISO |
[64Cu-CB-TE2A-Y3-TATE co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:22056254 |
|
NCBI chr10:102,136,283...102,143,449
Ensembl chr10:102,136,283...102,143,434
|
|
G |
St6gal2 |
ST6 beta-galactoside alpha-2,6-sialyltransferase 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ST6GAL2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 9:6,966,291...7,060,499
Ensembl chr 9:6,966,908...7,053,387
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions increases expression |
ISO |
[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein; Calcium inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]; Diltiazem promotes the reaction [Cyclic AMP results in increased expression of STAR protein]; Isradipine promotes the reaction [Cyclic AMP results in increased expression of STAR protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR mRNA]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]]; myricetin promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; Nifedipine promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR mRNA]; perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Verapamil promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Verapamil promotes the reaction [Cyclic AMP results in increased expression of STAR protein] Cyclic AMP results in increased expression of STAR mRNA; Cyclic AMP results in increased expression of STAR protein |
CTD |
PMID:19822634 PMID:20100736 PMID:25576683 PMID:28668616 |
|
NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
|
|
G |
Taar1 |
trace-amine-associated receptor 1 |
multiple interactions |
ISO |
[Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [phenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [tryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP [3-hydroxy-4-methoxyphenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [3-methoxytyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [3-tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [4-chloro-2-(imidazolin-2-yl)isoindoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [4-phenyl-1,2,3,4-tetrahydroisoquinoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [5-Methoxytryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [6-nitroquipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Antazoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [BE 2254 results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [cirazoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Clonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [efaroxan results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Fenoldopam results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Guanabenz results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [harman results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Histamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Idazoxan results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Methoxydimethyltryptamines results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [moxonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [N-methylquipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [O-methyltyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [phenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Quipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [rilmenidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tranylcypromine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [tryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tryptamines analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:19725810 |
|
NCBI chr 1:22,595,477...22,596,475
Ensembl chr 1:22,595,477...22,596,475
|
|
G |
Tas1r2 |
taste 1 receptor member 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TAS1R2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 5:158,119,894...158,135,733
Ensembl chr 5:158,042,587...158,135,733
|
|
G |
Tax1bp1 |
Tax1 binding protein 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TAX1BP1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 4:82,776,720...82,832,586
Ensembl chr 4:82,776,746...82,833,773
|
|
G |
Tex14 |
testis expressed 14, intercellular bridge forming factor |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TEX14 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr10:74,724,070...74,849,172
Ensembl chr10:74,724,549...74,849,194
|
|
G |
Tff1 |
trefoil factor 1 |
multiple interactions increases expression |
ISO |
CARM1 protein promotes the reaction [Cyclic AMP results in increased expression of TFF1 mRNA]; Cyclic AMP promotes the reaction [CARM1 protein binds to TFF1 promoter] |
CTD |
PMID:20360387 |
|
NCBI chr20:9,892,124...9,895,984
Ensembl chr20:9,892,124...9,895,984
|
|
G |
Tmsb15b2 |
thymosin beta 15B2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TMSB15B2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr X:107,612,518...107,614,632
Ensembl chr X:107,612,518...107,614,632
|
|
G |
Tmtc4 |
transmembrane O-mannosyltransferase targeting cadherins 4 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TMTC4 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr15:109,338,762...109,394,905
Ensembl chr15:109,339,564...109,394,927
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO |
Cyclic AMP results in decreased expression of TNF protein Cyclic AMP inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] [[S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:8550079 PMID:21266552 PMID:23566200 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfsf12 |
TNF superfamily member 12 |
decreases expression |
ISO |
Cyclic AMP results in decreased expression of TNFSF12 mRNA |
CTD |
PMID:22117073 |
|
NCBI chr10:56,290,780...56,300,137
Ensembl chr10:56,290,780...56,300,077
|
|
G |
Trpv4 |
transient receptor potential cation channel, subfamily V, member 4 |
increases expression multiple interactions |
EXP |
Cyclic AMP results in increased expression of TRPV4 mRNA; Cyclic AMP results in increased expression of TRPV4 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of TRPV4 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of TRPV4 protein] |
CTD |
PMID:22187434 |
|
NCBI chr12:47,698,915...47,737,902
Ensembl chr12:47,698,947...47,737,902
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions increases abundance |
ISO |
[Cobalt binds to dipyrido(3,2-a-2',3'-c)phenazine binds to N-(2-hydroxybenzyl)glycine analog] inhibits the reaction [TSHB protein results in increased abundance of Cyclic AMP]; [TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP; bisphenol A inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Diethylstilbestrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; resveratrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; TSHB protein inhibits the reaction [NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]] |
CTD |
PMID:19766106 PMID:21072367 PMID:21123444 |
|
NCBI chr 2:205,207,799...205,215,199
Ensembl chr 2:205,207,799...205,212,681
|
|
G |
Tshr |
thyroid stimulating hormone receptor |
multiple interactions increases abundance |
ISO |
[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP; bisphenol A inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Diethylstilbestrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]; resveratrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; TSHB protein inhibits the reaction [NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]] |
CTD |
PMID:19766106 PMID:21123444 |
|
NCBI chr 6:115,170,290...115,306,871
Ensembl chr 6:115,170,865...115,306,871
|
|
G |
Ttc6 |
tetratricopeptide repeat domain 6 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TTC6 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 6:78,567,453...78,779,151
Ensembl chr 6:78,567,970...78,631,557
|
|
G |
Uba5 |
ubiquitin-like modifier activating enzyme 5 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of UBA5 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 8:112,578,607...112,594,192
Ensembl chr 8:112,578,590...112,594,261
|
|
G |
Vash1 |
vasohibin 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VASH1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 6:110,624,377...110,640,942
Ensembl chr 6:110,624,856...110,637,382
|
|
G |
Vash2 |
vasohibin 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VASH2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr13:109,521,190...109,552,607
Ensembl chr13:109,521,190...109,552,589
|
|
G |
Vat1 |
vesicle amine transport 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VAT1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr10:89,366,898...89,374,516
Ensembl chr10:89,366,899...89,374,516
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Cyclic AMP affects the reaction [Norepinephrine results in increased expression of VEGFA mRNA] |
CTD |
PMID:10788502 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vip |
vasoactive intestinal peptide |
multiple interactions increases abundance |
ISO EXP |
[VIP protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP alpha-hexachlorocyclohexane inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]; Endrin inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]; Hexachlorocyclohexane inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP] VIP protein results in increased abundance of Cyclic AMP; VIP results in increased abundance of Cyclic AMP |
CTD |
PMID:1657658 PMID:2467674 PMID:7733904 PMID:20732086 |
|
NCBI chr 1:42,169,307...42,177,582
Ensembl chr 1:42,169,501...42,177,582
|
|
G |
Vipr2 |
vasoactive intestinal peptide receptor 2 |
multiple interactions |
ISO |
[ADCYAP1 protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP; [VIP protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:7733904 |
|
NCBI chr 6:143,932,960...144,009,476
Ensembl chr 6:143,938,040...144,008,072
|
|
G |
Wnt5a |
Wnt family member 5A |
multiple interactions |
ISO |
WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA]; WNT5A protein affects the reaction [Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] |
CTD |
PMID:20685861 |
|
NCBI chr16:4,469,451...4,490,271
Ensembl chr16:4,469,468...4,489,860
|
|
G |
Zfp36l2 |
zinc finger protein 36, C3H type-like 2 |
increases abundance |
ISO |
ZFP36L2 protein mutant form results in increased abundance of Cyclic AMP |
CTD |
PMID:24830504 |
|
NCBI chr 6:7,417,416...7,423,447
Ensembl chr 6:7,417,425...7,421,456
|
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases export increases transport multiple interactions |
ISO |
ABCC4 protein results in increased export of Cyclic GMP ABCC4 protein results in increased transport of Cyclic GMP daidzein inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Dipyridamole inhibits the reaction [ABCC4 protein results in increased transport of Cyclic GMP]; hesperetin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; naringenin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Probenecid inhibits the reaction [ABCC4 protein results in increased transport of Cyclic GMP]; Quercetin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; resveratrol inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Silymarin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP] |
CTD |
PMID:11856762 PMID:16156793 |
|
NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
|
|
G |
Agt |
angiotensinogen |
multiple interactions increases abundance |
EXP |
AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; AGT protein modified form inhibits the reaction [Streptozocin results in decreased abundance of Cyclic GMP]; vinpocetine inhibits the reaction [AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]] AGT protein modified form results in increased abundance of Cyclic GMP |
CTD |
PMID:11696475 PMID:28299329 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions |
EXP |
[PD 123319 results in decreased activity of AGTR2 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP] |
CTD |
PMID:16982965 |
|
NCBI chr X:119,389,480...119,393,845
Ensembl chr X:119,390,013...119,393,842
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
AKT1 protein inhibits the reaction [Carbon Tetrachloride results in decreased abundance of Cyclic GMP] |
CTD |
PMID:12891555 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
ISO |
ALDH2 protein affects the reaction [Nitroglycerin results in decreased abundance of Cyclic GMP] |
CTD |
PMID:17585900 |
|
NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
|
|
G |
Apoe |
apolipoprotein E |
decreases abundance |
ISO |
APOE gene mutant form results in decreased abundance of Cyclic GMP |
CTD |
PMID:11397713 |
|
NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
multiple interactions |
EXP |
[bradykinin, Leu(8)-des-Arg(9)- results in decreased activity of BDKRB1 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP] |
CTD |
PMID:16982965 |
|
NCBI chr 6:129,437,423...129,441,553
Ensembl chr 6:129,438,158...129,440,574
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
multiple interactions |
EXP |
[icatibant results in decreased activity of BDKRB2 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP] |
CTD |
PMID:16982965 |
|
NCBI chr 6:129,399,468...129,429,676
Ensembl chr 6:129,399,468...129,429,676
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
Cyclic GMP affects the reaction [Nitric Oxide results in decreased activity of CASP3 protein] |
CTD |
PMID:9388267 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP] |
CTD |
PMID:25490417 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cct7 |
chaperonin containing TCP1 subunit 7 |
multiple interactions |
ISO |
CCT7 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased abundance of Cyclic GMP] |
CTD |
PMID:24213632 |
|
NCBI chr 4:117,235,023...117,252,265
Ensembl chr 4:117,235,023...117,252,265
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions increases abundance |
EXP |
Puromycin Aminonucleoside inhibits the reaction [EDN1 protein results in increased abundance of Cyclic GMP] |
CTD |
PMID:12972712 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Edn3 |
endothelin 3 |
multiple interactions increases abundance |
EXP |
Puromycin Aminonucleoside promotes the reaction [EDN3 protein results in increased abundance of Cyclic GMP] |
CTD |
PMID:12972712 |
|
NCBI chr 3:172,856,730...172,879,276
Ensembl chr 3:172,856,733...172,880,450
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]; EPO protein inhibits the reaction [HPH1 gene mutant form results in decreased abundance of Cyclic GMP] |
CTD |
PMID:25041251 PMID:25490417 |
|
NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
|
|
G |
Gch1 |
GTP cyclohydrolase 1 |
affects abundance increases abundance multiple interactions |
ISO |
GCH1 protein affects the abundance of Cyclic GMP GCH1 gene mutant form results in increased abundance of Cyclic GMP CAT protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]; EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP] |
CTD |
PMID:21963838 PMID:25490417 |
|
NCBI chr15:23,935,011...23,968,971
Ensembl chr15:23,934,585...23,969,011
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
multiple interactions |
EXP |
[manganese chloride results in increased chemical synthesis of Cyclic GMP] which results in increased secretion of GNRH1 protein |
CTD |
PMID:17110411 PMID:17290048 |
|
NCBI chr15:44,441,856...44,446,064
Ensembl chr15:44,442,555...44,442,875 Ensembl chr15:44,442,555...44,442,875
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions increases abundance |
ISO |
[GUCY1A1 protein binds to GUCY1B1 protein] which results in increased chemical synthesis of Cyclic GMP; GUCY1A1 protein mutant form inhibits the reaction [3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole results in increased abundance of Cyclic GMP]; GUCY1A1 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased abundance of Cyclic GMP] GUCY1A1 gene mutant form results in increased abundance of Cyclic GMP |
CTD |
PMID:22171090 PMID:24213632 PMID:25373139 |
|
NCBI chr 2:181,045,694...181,103,321
Ensembl chr 2:181,045,703...181,102,918
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO |
[GUCY1A1 protein binds to GUCY1B1 protein] which results in increased chemical synthesis of Cyclic GMP |
CTD |
PMID:22171090 |
|
NCBI chr 2:180,976,939...181,026,001
Ensembl chr 2:180,976,939...181,026,024
|
|
G |
Hmox2 |
heme oxygenase 2 |
affects abundance |
ISO |
HMOX2 affects the abundance of Cyclic GMP |
CTD |
PMID:16181104 |
|
NCBI chr10:10,990,034...11,035,493
Ensembl chr10:10,990,034...11,035,484
|
|
G |
Il12rb2 |
interleukin 12 receptor subunit beta 2 |
increases expression |
ISO |
Cyclic GMP results in increased expression of IL12RB2 mRNA |
CTD |
PMID:12451176 |
|
NCBI chr 4:98,049,195...98,141,562
Ensembl chr 4:98,052,842...98,141,482
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases abundance |
EXP ISO |
Halothane inhibits the reaction [IL1B protein results in increased abundance of Cyclic GMP] [lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Cyclic GMP; nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Cyclic GMP] |
CTD |
PMID:11506125 PMID:14762100 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K1 protein] Cyclic GMP results in decreased phosphorylation of MAP2K1 protein |
CTD |
PMID:18225537 |
|
NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
decreases phosphorylation multiple interactions |
ISO |
Cyclic GMP results in decreased phosphorylation of MAP2K2 protein Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K2 protein] |
CTD |
PMID:18225537 |
|
NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases activity |
ISO |
Cyclic GMP analog results in increased activity of MAPK8 protein |
CTD |
PMID:11051267 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
[testosterone enanthate results in increased expression of NOS2 mRNA] which results in increased abundance of Cyclic GMP |
CTD |
PMID:20463352 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions increases abundance |
ISO EXP |
NOS3 protein affects the reaction [Ramipril results in increased abundance of Cyclic GMP] NOS3 protein results in increased abundance of Cyclic GMP |
CTD |
PMID:11504159 PMID:16891913 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions increases abundance |
ISO EXP |
Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K1 protein]; Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K2 protein] NPPA protein results in increased abundance of Cyclic GMP AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; carvedilol promotes the reaction [NPPA protein results in increased abundance of Cyclic GMP]; Puromycin Aminonucleoside inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; vinpocetine inhibits the reaction [AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]] |
CTD |
PMID:9421401 PMID:11696475 PMID:12022755 PMID:12582005 PMID:12972712 PMID:18225537 |
|
NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
|
|
G |
Nppc |
natriuretic peptide C |
increases chemical synthesis increases abundance multiple interactions |
EXP |
NPPC protein results in increased chemical synthesis of Cyclic GMP NPPC protein results in increased abundance of Cyclic GMP Ammonia inhibits the reaction [NPPC protein results in increased chemical synthesis of Cyclic GMP]; Fluoroacetates inhibits the reaction [NPPC protein results in increased abundance of Cyclic GMP] |
CTD |
PMID:17629948 PMID:18222015 |
|
NCBI chr 9:93,731,436...93,735,636
Ensembl chr 9:93,731,436...93,735,636
|
|
G |
Pde10a |
phosphodiesterase 10A |
multiple interactions increases hydrolysis |
ISO |
Cyclic AMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]; Cyclic GMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP] |
CTD |
PMID:10373451 |
|
NCBI chr 1:52,360,296...52,544,448
Ensembl chr 1:52,360,296...52,544,450
|
|
G |
Pde11a |
phosphodiesterase 11A |
multiple interactions increases hydrolysis |
ISO |
1-Methyl-3-isobutylxanthine inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP]; Dipyridamole inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP]; zaprinast inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP] |
CTD |
PMID:10725373 |
|
NCBI chr 3:62,818,502...63,211,843
Ensembl chr 3:62,818,502...63,211,845
|
|
G |
Pde1a |
phosphodiesterase 1A |
multiple interactions |
EXP |
PDE1A protein inhibits the reaction [Nitroglycerin results in increased abundance of Cyclic GMP] |
CTD |
PMID:11696475 |
|
NCBI chr 3:66,803,247...67,263,658
Ensembl chr 3:66,803,247...66,885,094
|
|
G |
Pde5a |
phosphodiesterase 5A |
decreases abundance |
ISO |
PDE5A protein results in decreased abundance of Cyclic GMP |
CTD |
PMID:10422958 |
|
NCBI chr 2:226,899,604...227,044,916
Ensembl chr 2:226,900,619...227,041,576
|
|
G |
Pde9a |
phosphodiesterase 9A |
increases hydrolysis multiple interactions |
ISO |
PDE9A protein results in increased hydrolysis of Cyclic GMP zaprinast inhibits the reaction [PDE9A protein results in increased hydrolysis of Cyclic GMP] |
CTD |
PMID:9624146 |
|
NCBI chr20:10,123,624...10,216,325
Ensembl chr20:10,123,651...10,216,548
|
|
G |
Pomc |
proopiomelanocortin |
affects abundance |
EXP |
POMC protein affects the abundance of Cyclic GMP |
CTD |
PMID:11193135 |
|
NCBI chr 6:28,382,937...28,388,771
Ensembl chr 6:28,382,962...28,388,967
|
|
G |
Ptpn12 |
protein tyrosine phosphatase, non-receptor type 12 |
increases activity |
EXP |
Cyclic GMP results in increased activity of PTPN12 protein |
CTD |
PMID:12714323 |
|
NCBI chr 4:10,631,129...10,702,390
Ensembl chr 4:10,631,073...10,702,386
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions |
ISO |
STK11 protein promotes the reaction [Histamine results in increased abundance of Cyclic GMP] |
CTD |
PMID:21145922 |
|
NCBI chr 7:12,440,751...12,457,513
Ensembl chr 7:12,440,751...12,457,513
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases abundance |
EXP |
7-(2-(4-(4-nitrobenzene)piperazinyl)ethyl)-1,3-dimethylxanthine inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP]; KMUP 1 inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP]; zaprinast inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP] |
CTD |
PMID:16754782 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases abundance |
ISO |
N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [VEGFA protein results in increased abundance of Cyclic GMP] |
CTD |
PMID:18575783 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
VIM protein affects the susceptibility to [Acetylcholine co-treated with Cyclic GMP co-treated with Indomethacin] |
CTD |
PMID:11588525 |
|
NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP |
[Xanthine co-treated with XDH protein] inhibits the reaction [Nitroprusside results in increased abundance of Cyclic GMP] |
CTD |
PMID:17339839 |
|
NCBI chr 6:25,149,570...25,211,273
Ensembl chr 6:25,149,235...25,211,494
|
|
|
G |
Nat2 |
N-acetyltransferase 2 |
multiple interactions |
ISO |
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] |
CTD |
PMID:20545351 |
|
NCBI chr16:23,960,709...23,991,570
Ensembl chr16:23,961,067...23,991,570
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone |
CTD |
PMID:20545351 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
P2ry1 |
purinergic receptor P2Y1 |
decreases activity |
ISO |
Phosphoadenosine Phosphosulfate results in decreased activity of P2RY1 protein |
CTD |
PMID:22273509 |
|
NCBI chr 2:151,314,818...151,320,312
Ensembl chr 2:151,314,818...151,320,319
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
multiple interactions increases sulfation |
ISO |
2,2',3,4,4',5',6-heptabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Halogenated Diphenyl Ethers analog inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; pentabrominated diphenyl ether 100 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; Pentachlorophenol inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tetrabromobisphenol A inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tribromodiphenyl ether 28 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein] SULT1A1 protein results in increased sulfation of Phosphoadenosine Phosphosulfate |
CTD |
PMID:11425650 PMID:16601080 PMID:20545351 |
|
NCBI chr 1:198,100,586...198,104,106
Ensembl chr 1:198,100,586...198,104,109
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
multiple interactions |
ISO |
[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol; Celecoxib affects the reaction [[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol]; SULT2A1 protein affects the metabolism of [Phosphoadenosine Phosphosulfate co-treated with Ethinyl Estradiol] |
CTD |
PMID:15483193 |
|
NCBI chr 1:76,558,721...76,614,315
Ensembl chr 1:76,252,329...76,780,230
|
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
affects binding multiple interactions |
ISO |
7-methylguanosine 5'-diphosphate analog binds to EIF4E protein 7-methylguanosine triphosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; 7-methylguanosine-5'-monophosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Guanosine analog inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Quinolones inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Sulfonamides inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein] |
CTD |
PMID:27592390 |
|
NCBI chr 2:243,819,616...243,853,987
Ensembl chr 2:243,820,661...243,852,631
|
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
7-methylguanosine triphosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; 7-methylguanosine triphosphate inhibits the reaction [RNA Caps binds to EIF4E protein] |
CTD |
PMID:27592390 |
|
NCBI chr 2:243,819,616...243,853,987
Ensembl chr 2:243,820,661...243,852,631
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions affects binding |
ISO |
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate]; Sirolimus promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate] |
CTD |
PMID:25940091 |
|
NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
|
|
G |
Eif4g1 |
eukaryotic translation initiation factor 4 gamma, 1 |
multiple interactions affects binding |
ISO |
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate]; Sirolimus inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate] |
CTD |
PMID:25940091 |
|
NCBI chr11:83,907,659...83,927,683
Ensembl chr11:83,908,109...83,926,524
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions increases expression |
ISO |
Mevalonic Acid inhibits the reaction [mevastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein]]; pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein] |
CTD |
PMID:16415093 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCB11 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCB1A mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCC2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCG2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of AKT1 protein |
CTD |
PMID:20610540 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Bcl2l11 |
BCL2 like 11 |
increases expression increases response to substance |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of BCL2L11 mRNA; 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of BCL2L11 protein BCL2L11 protein results in increased susceptibility to 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP |
CTD |
PMID:14996839 |
|
NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased activity of CASP3 protein |
CTD |
PMID:14996839 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cfl1 |
cofilin 1 |
decreases phosphorylation |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in decreased phosphorylation of CFL1 protein |
CTD |
PMID:20610540 |
|
NCBI chr 1:220,869,805...220,873,337
Ensembl chr 1:220,869,805...220,873,337
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein mutant form; [5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein mutant form |
CTD |
PMID:15163550 |
|
NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions increases phosphorylation |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of and results in increased activity of CREB1 protein 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of CREB1 protein |
CTD |
PMID:14741741 PMID:20610540 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NFE2L2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
multiple interactions |
ISO |
NR1H2 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]] |
CTD |
PMID:16415093 |
|
NCBI chr 1:100,554,577...100,559,896
Ensembl chr 1:100,554,544...100,559,942
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
NR1H3 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]] |
CTD |
PMID:16415093 |
|
NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NR1I2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NR1I3 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions decreases activity |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP inhibits the reaction [RHOA protein binds to RTKN protein] 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in decreased activity of RHOA protein |
CTD |
PMID:20610540 |
|
NCBI chr 8:117,082,440...117,116,244
Ensembl chr 8:117,106,576...117,116,167
|
|
G |
Rtkn |
rhotekin |
multiple interactions |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP inhibits the reaction [RHOA protein binds to RTKN protein] |
CTD |
PMID:20610540 |
|
NCBI chr 4:114,833,453...114,850,705
Ensembl chr 4:114,835,064...114,850,701
|
|
G |
Scnn1a |
sodium channel epithelial 1 subunit alpha |
multiple interactions |
EXP |
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] |
CTD |
PMID:15161604 |
|
NCBI chr 4:157,834,339...157,860,472
Ensembl chr 4:157,836,912...157,860,049
|
|
G |
Scnn1b |
sodium channel epithelial 1 subunit beta |
multiple interactions |
EXP |
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] |
CTD |
PMID:15161604 |
|
NCBI chr 1:191,829,547...191,883,991
Ensembl chr 1:191,829,555...191,884,298
|
|
G |
Scnn1g |
sodium channel epithelial 1 subunit gamma |
multiple interactions |
EXP |
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] |
CTD |
PMID:15161604 |
|
NCBI chr 1:191,704,397...191,738,271
Ensembl chr 1:191,704,311...191,738,268
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLC10A1 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 6:104,617,730...104,631,355
Ensembl chr 6:104,617,730...104,631,355
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLCO1A4 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 4:175,969,549...176,026,227
Ensembl chr 4:175,969,549...176,026,163
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLCO1B2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 4:175,814,118...175,881,775
Ensembl chr 4:175,814,118...175,881,768
|
|
G |
Snap25 |
synaptosome associated protein 25 |
multiple interactions affects splicing |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP affects the splicing of SNAP25 exon] |
CTD |
PMID:22684629 |
|
NCBI chr 3:129,697,408...129,788,417
Ensembl chr 3:129,599,353...129,788,400
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP promotes the reaction [Capsaicin results in increased activity of TRPV1] |
CTD |
PMID:12886029 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
G |
Vip |
vasoactive intestinal peptide |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of VIP mRNA |
CTD |
PMID:2156696 |
|
NCBI chr 1:42,169,307...42,177,582
Ensembl chr 1:42,169,501...42,177,582
|
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of ALOX15 mRNA; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of ALOX15 protein |
CTD |
PMID:16166323 |
|
NCBI chr10:56,953,692...56,962,145
Ensembl chr10:56,953,691...56,962,161
|
|
G |
Arhgef17 |
Rho guanine nucleotide exchange factor 17 |
multiple interactions |
ISO |
2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein; [calyculin A co-treated with Okadaic Acid] inhibits the reaction [2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]]; KT 5823 inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]]; Y 27632 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein] |
CTD |
PMID:23195829 |
|
Ensembl chr 1:165,911,718...165,967,069
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression multiple interactions |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of CEBPB protein 8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of CEBPB protein] |
CTD |
PMID:20471953 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression multiple interactions |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of FABP4 protein 8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of FABP4 protein] |
CTD |
PMID:20471953 |
|
NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein alternative form] inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] |
CTD |
PMID:11799084 |
|
NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
ISO |
8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of PPARG protein] |
CTD |
PMID:20471953 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Prkg1 |
protein kinase cGMP-dependent 1 |
multiple interactions increases activity decreases expression |
ISO EXP |
2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein; [calyculin A co-treated with Okadaic Acid] inhibits the reaction [2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]]; KT 5823 inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]]; KT 5823 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein]; Y 27632 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein] [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein alternative form] inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of PRKG1 protein 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased expression of PRKG1 protein; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased expression of PRKG1 protein alternative form |
CTD |
PMID:9366573 PMID:11799084 PMID:23195829 |
|
NCBI chr 1:248,982,039...250,300,952
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
ISO |
[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein; KT 5823 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein] |
CTD |
PMID:23195829 |
|
NCBI chr 8:117,082,440...117,116,244
Ensembl chr 8:117,106,576...117,116,167
|
|
G |
Scnn1a |
sodium channel epithelial 1 subunit alpha |
multiple interactions |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D] |
CTD |
PMID:19359370 |
|
NCBI chr 4:157,834,339...157,860,472
Ensembl chr 4:157,836,912...157,860,049
|
|
G |
Scnn1b |
sodium channel epithelial 1 subunit beta |
multiple interactions |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D] |
CTD |
PMID:19359370 |
|
NCBI chr 1:191,829,547...191,883,991
Ensembl chr 1:191,829,555...191,884,298
|
|
G |
Scnn1g |
sodium channel epithelial 1 subunit gamma |
multiple interactions |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D] |
CTD |
PMID:19359370 |
|
NCBI chr 1:191,704,397...191,738,271
Ensembl chr 1:191,704,311...191,738,268
|
|
G |
Srf |
serum response factor |
multiple interactions |
ISO |
[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein |
CTD |
PMID:23195829 |
|
NCBI chr 9:16,737,637...16,747,226
Ensembl chr 9:16,737,642...16,747,225
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
increases phosphorylation decreases phosphorylation |
ISO EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased phosphorylation of VASP protein 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased phosphorylation of VASP protein |
CTD |
PMID:11799084 PMID:16166323 |
|
NCBI chr 1:80,170,608...80,185,882
Ensembl chr 1:80,170,619...80,185,882
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ABCA1 protein |
CTD |
PMID:17478430 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA] |
CTD |
PMID:27743861 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCC1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA] |
CTD |
PMID:27743861 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcd2 |
ATP binding cassette subfamily D member 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCD2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:132,294,564...132,343,169
Ensembl chr 7:132,294,562...132,343,169
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCG1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:9,743,269...9,842,735
Ensembl chr20:9,743,269...9,840,489
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA] |
CTD |
PMID:30610963 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Ablim1 |
actin-binding LIM protein 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABLIM1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:277,853,877...278,043,096
|
|
G |
Ablim2 |
actin binding LIM protein family, member 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ABLIM2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:80,044,217...80,169,491
Ensembl chr14:80,045,078...80,169,472
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ACAT2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:47,972,399...47,992,654
Ensembl chr 1:47,972,399...47,992,653
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ACE2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:32,050,734...32,095,860
Ensembl chr X:32,049,931...32,096,016
|
|
G |
Acp3 |
acid phosphatase 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ACP3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:112,838,574...112,884,062
Ensembl chr 8:112,834,707...112,884,077
|
|
G |
Adamts6 |
ADAM metallopeptidase with thrombospondin type 1 motif, 6 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADAMTS6 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr 2:34,374,142...34,589,676
Ensembl chr 2:34,374,158...34,586,755
|
|
G |
Adamts8 |
ADAM metallopeptidase with thrombospondin type 1 motif, 8 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADAMTS8 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:32,017,684...32,037,529
Ensembl chr 8:32,018,560...32,037,531
|
|
G |
Adcy7 |
adenylate cyclase 7 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADCY7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:19,702,307...19,762,973
Ensembl chr19:19,704,859...19,727,081
|
|
G |
Adgrd1 |
adhesion G protein-coupled receptor D1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADGRD1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:31,134,806...31,249,594
Ensembl chr12:31,136,741...31,249,118
|
|
G |
Adgrf5 |
adhesion G protein-coupled receptor F5 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADGRF5 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 9:20,091,121...20,195,706
Ensembl chr 9:20,091,099...20,195,566
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADGRG1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:10,423,534...10,460,674
Ensembl chr19:10,423,501...10,460,674
|
|
G |
Adgrg2 |
adhesion G protein-coupled receptor G2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADGRG2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:36,930,186...37,054,968
Ensembl chr X:36,930,186...37,003,642
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADRA2A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:274,766,283...274,769,083
Ensembl chr 1:274,766,283...274,769,081
|
|
G |
Agr2 |
anterior gradient 2, protein disulphide isomerase family member |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of AGR2 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 6:55,465,782...55,487,087
Ensembl chr 6:55,465,782...55,487,714
|
|
G |
Agt |
angiotensinogen |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AGT mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AGTR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:35,907,102...35,958,136
Ensembl chr17:35,907,108...35,958,077
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AHR mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AIFM1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:135,304,063...135,343,062
Ensembl chr X:135,304,066...135,343,087
|
|
G |
Akap2 |
A-kinase anchoring protein 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PALM2AKAP2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:74,874,245...74,985,789
Ensembl chr 5:74,874,306...74,982,401
|
|
G |
Akap7 |
A-kinase anchoring protein 7 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of AKAP7 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 1:21,129,213...21,263,850
Ensembl chr 1:21,141,970...21,263,850
|
|
G |
Akap9 |
A-kinase anchoring protein 9 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AKAP9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:27,195,346...27,331,582
Ensembl chr 4:27,195,346...27,331,582
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AKT1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alb |
albumin |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ALB mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ALDH1A1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Angpt1 |
angiopoietin 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ANGPT1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 7:81,338,327...81,592,459
Ensembl chr 7:81,342,280...81,592,206
|
|
G |
Angptl1 |
angiopoietin-like 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ANGPTL1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:74,456,487...74,463,031
Ensembl chr13:74,410,010...74,474,681
|
|
G |
Ankh |
ANKH inorganic pyrophosphate transport regulator |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ANKH mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 2:80,131,563...80,256,948
Ensembl chr 2:80,131,563...80,256,954
|
|
G |
Anxa8 |
annexin A8 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of ANXA8 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr16:10,417,174...10,432,388
Ensembl chr16:10,417,185...10,432,393
|
|
G |
Aopep |
aminopeptidase O |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AOPEP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:507,389...825,062
Ensembl chr17:507,377...821,582
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APAF1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
|
|
G |
Apbb1ip |
amyloid beta precursor protein binding family B member 1 interacting protein |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of APBB1IP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:90,098,953...90,149,192
Ensembl chr17:90,099,025...90,149,894
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APC mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:27,011,710...27,106,323
Ensembl chr18:27,047,382...27,105,531
|
|
G |
Apcdd1 |
APC down-regulated 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APCDD1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:58,270,398...58,300,982
Ensembl chr18:58,270,410...58,301,002
|
|
G |
Ar |
androgen receptor |
decreases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AR mRNA [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of AR mRNA; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of AR mRNA] |
CTD |
PMID:18467523 PMID:22079614 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Areg |
amphiregulin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AREG mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr14:18,521,921...18,531,179
Ensembl chr14:18,521,930...18,531,179
|
|
G |
Arhgef2 |
Rho/Rac guanine nucleotide exchange factor 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ARHGEF2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:187,964,100...188,022,847
Ensembl chr 2:187,977,008...188,021,377
|
|
G |
Arhgef4 |
Rho guanine nucleotide exchange factor 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARHGEF4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:41,160,562...41,305,015
Ensembl chr 9:41,295,909...41,302,501
|
|
G |
Arid5b |
AT-rich interaction domain 5B |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ARID5B mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:21,713,900...21,881,193
Ensembl chr20:21,564,975...21,880,715
|
|
G |
Armcx3 |
armadillo repeat containing, X-linked 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARMCX3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:105,573,909...105,577,480
Ensembl chr X:105,573,909...105,580,562
|
|
G |
Armcx4 |
armadillo repeat containing, X-linked 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARMCX4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:105,497,277...105,507,636
Ensembl chr X:105,500,173...105,507,288
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ASNS mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:33,742,876...33,761,106
Ensembl chr 4:33,743,364...33,761,163
|
|
G |
Atp4a |
ATPase H+/K+ transporting subunit alpha |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ATP4A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:89,162,700...89,175,504
Ensembl chr 1:89,162,639...89,175,811
|
|
G |
Avpi1 |
arginine vasopressin-induced 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AVPI1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:261,365,590...261,371,519
Ensembl chr 1:261,365,590...261,371,508
|
|
G |
B4galnt3 |
beta-1,4-N-acetyl-galactosaminyl transferase 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of B4GALNT3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:152,736,036...152,835,521
Ensembl chr 4:152,737,161...152,835,182
|
|
G |
Bank1 |
B-cell scaffold protein with ankyrin repeats 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BANK1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:241,273,763...241,545,527
Ensembl chr 2:241,273,763...241,545,250
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BAX [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BAX protein |
CTD |
PMID:11802967 PMID:16709600 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BCAT1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:179,259,305...179,340,021
Ensembl chr 4:179,259,308...179,339,795
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BCL2 |
CTD |
PMID:11802967 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l11 |
BCL2 like 11 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BCL2L11 protein |
CTD |
PMID:16709600 |
|
NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BDKRB1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 6:129,437,423...129,441,553
Ensembl chr 6:129,438,158...129,440,574
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BDKRB2 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 6:129,399,468...129,429,676
Ensembl chr 6:129,399,468...129,429,676
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BMP4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:20,776,060...20,791,013
Ensembl chr15:20,776,054...20,822,740
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
decreases expression increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BMP6 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BMP6 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr17:26,955,142...27,112,820
Ensembl chr17:26,955,142...27,112,820
|
|
G |
Brinp1 |
BMP/retinoic acid inducible neural specific 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BRINP1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 5:84,919,416...85,123,828
Ensembl chr 5:84,919,367...85,123,829
|
|
G |
Btbd9 |
BTB domain containing 9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BTBD9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:8,899,286...9,253,936
Ensembl chr20:8,901,931...9,249,820
|
|
G |
Cables1 |
Cdk5 and Abl enzyme substrate 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CABLES1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:3,317,724...3,421,721
Ensembl chr18:3,317,724...3,421,721
|
|
G |
Cabp7 |
calcium binding protein 7 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CABP7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:84,968,125...84,978,242
Ensembl chr14:84,968,130...84,978,255
|
|
G |
Cadm1 |
cell adhesion molecule 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CADM1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:51,858,906...52,200,591
Ensembl chr 8:52,127,399...52,189,722
|
|
G |
Cadm2 |
cell adhesion molecule 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CADM2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:4,175,078...4,397,335
Ensembl chr11:4,174,881...4,397,361
|
|
G |
Caln1 |
calneuron 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CALN1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:29,307,117...29,796,996
Ensembl chr12:29,308,341...29,743,705
|
|
G |
Calr |
calreticulin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CALR mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:25,956,771...25,961,666
Ensembl chr19:25,956,771...25,961,666
|
|
G |
Camk2n1 |
calcium/calmodulin-dependent protein kinase II inhibitor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAMK2N1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:156,876,706...156,878,486
Ensembl chr 5:156,876,706...156,878,486
|
|
G |
Capn15 |
calpain 15 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CAPN15 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:15,319,772...15,346,607
Ensembl chr10:15,319,774...15,346,374
|
|
G |
Capn2 |
calpain 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAPN2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:100,878,649...100,928,811
Ensembl chr13:100,878,650...100,928,811
|
|
G |
Capn6 |
calpain 6 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAPN6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:115,049,113...115,073,824
Ensembl chr X:115,049,154...115,073,890
|
|
G |
Card14 |
caspase recruitment domain family, member 14 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CARD14 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:108,440,480...108,469,012
Ensembl chr10:108,440,950...108,468,310
|
|
G |
Cars |
cysteinyl-tRNA synthetase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CARS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:216,759,367...216,801,652
Ensembl chr 1:216,759,366...216,801,656
|
|
G |
Casp3 |
caspase 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CASP3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CASP9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CAT mRNA |
CTD |
PMID:16709600 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cbr4 |
carbonyl reductase 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CBR4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:31,944,328...31,972,553
Ensembl chr16:31,956,753...31,972,507
|
|
G |
Ccdc170 |
coiled-coil domain containing 170 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCDC170 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:42,216,594...42,256,837 NCBI chr 1:41,033,284...41,133,299
Ensembl chr 1:41,034,308...41,126,043
|
|
G |
Ccdc3 |
coiled-coil domain containing 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCDC3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:76,991,722...77,093,515
Ensembl chr17:76,995,043...77,093,308
|
|
G |
Ccdc80 |
coiled-coil domain containing 80 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCDC80 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:60,645,660...60,679,249
Ensembl chr11:60,645,086...60,679,555
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1A protein results in increased secretion of CCL2 protein]]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]]; [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of CCL2 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCL2 protein |
CTD |
PMID:11230753 PMID:16997883 PMID:20940016 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Reactive Oxygen Species results in increased expression of CCL5 mRNA]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA] |
CTD |
PMID:10495789 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Ccn3 |
cellular communication network factor 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCN3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:94,375,134...94,382,154
Ensembl chr 7:94,375,020...94,383,024
|
|
G |
Ccn6 |
cellular communication network factor 6 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCN6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:44,237,491...44,255,064
Ensembl chr20:44,237,491...44,255,064
|
|
G |
Ccna1 |
cyclin A1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCNA1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:144,456,689...144,503,570
Ensembl chr 2:144,458,153...144,467,912
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCND2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
|
|
G |
Cd244 |
CD244 molecule |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD244 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:89,959,091...89,995,993
Ensembl chr13:89,975,267...89,995,974
|
|
G |
Cd74 |
CD74 molecule |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD74 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:56,071,420...56,080,851
Ensembl chr18:56,071,478...56,080,849
|
|
G |
Cd9 |
CD9 molecule |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:157,977,163...158,010,091
Ensembl chr 4:157,977,162...158,010,166
|
|
G |
Cdh22 |
cadherin 22 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDH22 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:161,574,993...161,971,102
Ensembl chr 3:161,575,631...161,917,285
|
|
G |
Cdh4 |
cadherin 4 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDH4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:175,220,520...175,283,144
Ensembl chr 3:175,144,495...175,279,761
|
|
G |
Cdh6 |
cadherin 6 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CDH6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:63,100,723...63,246,618
Ensembl chr 2:63,101,739...63,166,509
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDK2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDKN1A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdon |
cell adhesion associated, oncogene regulated |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CDON mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 8:36,625,757...36,712,091
Ensembl chr 8:36,625,733...36,710,949
|
|
G |
Cdx1 |
caudal type homeo box 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDX1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:56,337,485...56,355,477
Ensembl chr18:56,338,336...56,355,490
|
|
G |
Ceacam6 |
CEA cell adhesion molecule 6 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEACAM6 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 1:81,683,500...81,701,230
Ensembl chr 1:81,683,463...81,701,317
|
|
G |
Cebpg |
CCAAT/enhancer binding protein gamma |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CEBPG mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:91,286,956...91,297,459
Ensembl chr 1:91,287,917...91,296,656
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CFLAR protein alternative form |
CTD |
PMID:16709600 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
increases expression |
EXP ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CGA mRNA |
CTD |
PMID:8404651 PMID:21467749 PMID:22079614 |
|
NCBI chr 5:50,362,491...50,393,368
Ensembl chr 5:50,381,244...50,393,367
|
|
G |
Cgn |
cingulin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CGN mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:195,909,691...195,937,130
Ensembl chr 2:195,909,626...195,935,878
|
|
G |
Chn1 |
chimerin 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CHN1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:60,512,360...60,668,413
Ensembl chr 3:60,513,077...60,611,924
|
|
G |
Chp1 |
calcineurin-like EF-hand protein 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CHP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:111,354,506...111,389,998
Ensembl chr 3:111,354,506...111,389,989
|
|
G |
Cidea |
cell death-inducing DFFA-like effector a |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CIDEA mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:63,082,861...63,108,450
Ensembl chr18:63,098,144...63,108,051
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CIDEC protein |
CTD |
PMID:21097823 |
|
NCBI chr 4:145,377,482...145,390,497
Ensembl chr 4:145,377,431...145,390,497
|
|
G |
Ckmt2 |
creatine kinase, mitochondrial 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CKMT2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:21,422,680...21,452,797
Ensembl chr 2:21,422,818...21,437,193
|
|
G |
Cldn1 |
claudin 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CLDN1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:77,815,216...77,830,373
Ensembl chr11:77,815,181...77,830,416
|
|
G |
Cldn5 |
claudin 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLDN5 mRNA |
CTD |
PMID:20711499 |
|
NCBI chr11:86,356,292...86,357,718
Ensembl chr11:86,356,294...86,357,718
|
|
G |
Clgn |
calmegin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLGN mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr19:24,545,257...24,578,527
Ensembl chr19:24,545,318...24,576,798
|
|
G |
Clic3 |
chloride intracellular channel 3 |
multiple interactions increases expression |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CLIC3 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLIC3 mRNA |
CTD |
PMID:16997883 PMID:22079614 |
|
NCBI chr 3:2,675,732...2,678,248
Ensembl chr 3:2,676,296...2,680,565
|
|
G |
Cmklr1 |
chemerin chemokine-like receptor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CMKLR1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr12:48,743,556...48,796,582
Ensembl chr12:48,789,261...48,793,553
|
|
G |
Cnih3 |
cornichon family AMPA receptor auxiliary protein 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CNIH3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:99,663,150...99,770,625
Ensembl chr13:99,663,150...99,770,625
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CNR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Col15a1 |
collagen type XV alpha 1 chain |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL15A1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 5:62,840,360...62,950,240
|
|
G |
Col4a4 |
collagen type IV alpha 4 chain |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of COL4A4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:88,314,763...88,357,183
Ensembl chr 9:88,232,455...88,357,182
|
|
G |
Col4a6 |
collagen type IV alpha 6 chain |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL4A6 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr X:112,405,647...112,768,337
Ensembl chr X:112,405,647...112,473,822
|
|
G |
Col6a3 |
collagen type VI alpha 3 chain |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of COL6A3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:97,926,784...98,004,643
Ensembl chr 9:97,926,787...98,004,546
|
|
G |
Col7a1 |
collagen type VII alpha 1 chain |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL7A1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 8:117,694,441...117,726,844
Ensembl chr 8:117,694,605...117,726,844
|
|
G |
Colec12 |
collectin sub-family member 12 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of COLEC12 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:867,048...1,054,047
Ensembl chr18:867,048...1,052,606
|
|
G |
Coro2a |
coronin 2A |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CORO2A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:62,154,526...62,210,797
Ensembl chr 5:62,156,839...62,187,930
|
|
G |
Cpm |
carboxypeptidase M |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CPM mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:60,654,350...60,714,620
Ensembl chr 7:60,654,350...60,714,620
|
|
G |
Cpo |
carboxypeptidase O |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CPO mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:70,603,023...70,641,290
|
|
G |
Cradd |
CASP2 and RIPK1 domain containing adaptor with death domain |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CRADD mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:36,395,665...36,408,588
Ensembl chr 7:36,395,665...36,408,588
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of CREB1 protein |
CTD |
PMID:18467523 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Testosterone]] |
CTD |
PMID:2153673 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Crhbp |
corticotropin releasing hormone binding protein |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CRHBP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:25,141,471...25,153,334
Ensembl chr 2:25,141,471...25,153,334
|
|
G |
Cst6 |
cystatin E/M |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of CST6 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 1:220,727,292...220,729,000
Ensembl chr 1:220,727,292...220,729,000
|
|
G |
Ctnna2 |
catenin alpha 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CTNNA2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:107,880,611...109,042,724
Ensembl chr 4:107,881,826...108,008,484
|
|
G |
Cttnbp2 |
cortactin binding protein 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CTTNBP2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:42,932,897...43,096,454
Ensembl chr 4:42,932,903...43,096,399
|
|
G |
Cux2 |
cut-like homeobox 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CUX2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:40,016,774...40,221,067
Ensembl chr12:40,018,937...40,219,291
|
|
G |
Cx3cl1 |
C-X3-C motif chemokine ligand 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CX3CL1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:10,644,267...10,654,861
Ensembl chr19:10,644,244...10,653,800
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CXCL10 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CXCL12 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CXCL12 mRNA |
CTD |
PMID:20711499 PMID:22079614 |
|
NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
|
|
G |
Cycs |
cytochrome c, somatic |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYCS mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions increases expression increases activity |
ISO EXP |
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]]; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA; Hydrocarbons, Chlorinated inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP11A1 protein 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP11A1 protein] |
CTD |
PMID:20147733 PMID:21126571 PMID:21610156 PMID:21664964 PMID:21726595 PMID:22546480 PMID:24014645 PMID:24328340 PMID:24740604 |
|
NCBI chr 8:62,798,317...62,809,848
Ensembl chr 8:62,779,875...62,809,893
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11B1 mRNA Mitotane affects the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11B1 mRNA] |
CTD |
PMID:22079614 PMID:22172629 PMID:22546480 |
|
NCBI chr 7:116,248,759...116,255,205
Ensembl chr 7:116,156,219...116,255,167
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11B2 mRNA [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11B1 mRNA |
CTD |
PMID:21610156 PMID:22079614 |
|
NCBI chr 7:116,155,928...116,161,781
Ensembl chr 7:116,156,219...116,255,167
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
[4-nitro-3-phenylphenol co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of CYP17A1 protein; Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]]; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP17A1 mRNA; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein] |
CTD |
PMID:18336853 PMID:21610156 PMID:21726595 PMID:22079614 PMID:22546480 PMID:24014645 |
|
NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions increases expression increases activity |
EXP ISO |
[vinclozolin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP19A1 mRNA; Atrazine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; Atrazine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 mRNA]; bisphenol A inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; formestane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; Methoxychlor inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein] [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP19A1 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 protein |
CTD |
PMID:10746939 PMID:18815356 PMID:21126571 PMID:21610156 PMID:22120136 PMID:23583632 PMID:28859905 PMID:30951242 |
|
NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 protein |
CTD |
PMID:7588239 PMID:22079614 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp21a1 |
cytochrome P450, family 21, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP21A1 mRNA |
CTD |
PMID:21610156 |
|
NCBI chr20:4,486,213...4,489,358
Ensembl chr20:4,486,219...4,489,550
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:81,968,285...81,998,213
Ensembl chr 9:81,968,332...81,998,169
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP2E1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp2f4 |
cytochrome P450, family 2, subfamily f, polypeptide 4 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP2F1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:83,933,974...83,947,804
Ensembl chr 1:83,933,942...83,947,821
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP3A5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP51A1 mRNA [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 mRNA; [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 protein; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 mRNA]; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 protein] |
CTD |
PMID:18467523 PMID:22079614 |
|
NCBI chr 4:27,175,564...27,194,018
Ensembl chr 4:27,175,243...27,194,018
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP8B1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:130,548,418...130,550,388
Ensembl chr 8:130,548,418...130,550,388
|
|
G |
Cyth1 |
cytohesin 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYTH1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:107,197,983...107,281,285
Ensembl chr10:107,197,989...107,281,235
|
|
G |
Dach2 |
dachshund family transcription factor 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DACH2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:84,924,570...85,484,150
Ensembl chr X:85,338,928...85,483,719
|
|
G |
Dact1 |
dishevelled-binding antagonist of beta-catenin 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DACT1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:93,740,440...93,751,003
Ensembl chr 6:93,740,586...93,749,809
|
|
G |
Dcaf12l1 |
DDB1 and CUL4 associated factor 12-like 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DCAF12L1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:131,340,045...131,344,038
Ensembl chr X:131,340,045...131,343,853
|
|
G |
Dcbld2 |
discoidin, CUB and LCCL domain containing 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DCBLD2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:44,237,814...44,292,884
Ensembl chr11:44,241,111...44,292,884
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DGAT2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:164,113,459...164,143,818
Ensembl chr 1:164,113,459...164,143,818
|
|
G |
Dgkb |
diacylglycerol kinase, beta |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DGKB mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:57,516,351...58,277,385
Ensembl chr 6:57,516,713...58,277,279
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DHCR24 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:126,164,708...126,188,926
Ensembl chr 5:126,164,674...126,191,206
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DHCR7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:217,018,916...217,034,890
Ensembl chr 1:217,018,916...217,034,904
|
|
G |
Dhrs2 |
dehydrogenase/reductase 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DHRS2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:33,876,701...33,891,559
Ensembl chr15:33,885,106...33,891,539
|
|
G |
Dhrs3 |
dehydrogenase/reductase 3 |
multiple interactions |
ISO |
7-propyl spirolactone inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein]; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of DHRS3 mRNA; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein; Aldosterone promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of DHRS3 mRNA] |
CTD |
PMID:23275455 |
|
NCBI chr 5:162,809,090...162,843,385
Ensembl chr 5:162,808,646...162,843,383
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions increases activity |
ISO EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of and results in increased activity of DIO2 protein 8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein Acetylcysteine inhibits the reaction [Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]]; Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]; Sodium Selenite inhibits the reaction [Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]] |
CTD |
PMID:11425850 PMID:18420745 |
|
NCBI chr 6:114,475,156...114,489,443
Ensembl chr 6:114,476,142...114,476,723
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [[Hydrogen Peroxide co-treated with Sodium Selenite] promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein]]; Acetylcysteine inhibits the reaction [Hydrogen Peroxide promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein]]; Hydrogen Peroxide promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein] |
CTD |
PMID:18420745 |
|
NCBI chr 6:134,627,278...134,629,139
Ensembl chr 6:134,627,278...134,629,138
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DKK1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:248,952,896...248,956,579
Ensembl chr 1:248,895,738...248,898,607
|
|
G |
Dnah5 |
dynein, axonemal, heavy chain 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNAH5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:80,947,730...81,143,997 NCBI chr 2:81,159,060...81,337,560
Ensembl chr 2:80,948,658...81,143,447
|
|
G |
Dnajb3 |
DnaJ heat shock protein family (Hsp40) member B3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DNAJB3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:95,289,918...95,290,931
Ensembl chr 9:95,289,918...95,290,931
|
|
G |
Dnajb7 |
DnaJ heat shock protein family (Hsp40) member B7 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNAJB7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:122,642,740...122,644,054
Ensembl chr 7:122,642,740...122,644,054
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNAJB9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:64,165,913...64,170,122
Ensembl chr 6:64,165,913...64,170,151
|
|
G |
Dner |
delta/notch-like EGF repeat containing |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNER mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:91,965,866...92,291,172
Ensembl chr 9:91,965,866...92,291,220
|
|
G |
Dock11 |
dedicator of cytokinesis 11 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DOCK11 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:122,507,169...122,690,463
Ensembl chr X:122,507,374...122,690,465
|
|
G |
Dok5 |
docking protein 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DOK5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:168,345,116...168,482,445
Ensembl chr 3:168,345,152...168,482,441
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DUSP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:16,970,642...16,973,425
Ensembl chr10:16,970,626...16,973,418
|
|
G |
Dusp16 |
dual specificity phosphatase 16 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DUSP16 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:168,470,141...168,551,346
Ensembl chr 4:168,472,412...168,517,177
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DUSP4 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr16:61,080,767...61,090,973
Ensembl chr16:61,078,175...61,091,169
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DUSP6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:41,475,163...41,479,393
Ensembl chr 7:41,475,163...41,479,392
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EBP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:15,049,394...15,055,782
Ensembl chr X:15,049,462...15,055,781
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ECHS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:212,570,213...212,579,040
Ensembl chr 1:212,570,195...212,579,057
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]] |
CTD |
PMID:18467523 |
|
NCBI chr 2:68,820,616...68,895,537
|
|
G |
Egfr |
epidermal growth factor receptor |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EGFR mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EGR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Egr2 |
early growth response 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EGR2 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr20:22,452,170...22,461,018
Ensembl chr20:22,454,463...22,459,025
|
|
G |
Elp1 |
elongator acetyltransferase complex subunit 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ELP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:73,503,406...73,552,798
Ensembl chr 5:73,503,407...73,552,798
|
|
G |
Emp2 |
epithelial membrane protein 2 |
multiple interactions decreases expression |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of EMP2 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EMP2 mRNA |
CTD |
PMID:16997883 PMID:22079614 |
|
NCBI chr10:5,433,248...5,467,840
Ensembl chr10:5,433,248...5,467,839
|
|
G |
Enox1 |
ecto-NOX disulfide-thiol exchanger 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ENOX1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr15:59,331,134...59,884,512
Ensembl chr15:59,678,165...59,884,511
|
|
G |
Ep300 |
E1A binding protein p300 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EP300 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:122,818,194...122,889,055
Ensembl chr 7:122,818,975...122,861,296
|
|
G |
Epg5 |
ectopic P-granules autophagy protein 5 homolog |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EPG5 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr18:74,299,965...74,397,115
Ensembl chr18:74,299,931...74,395,547
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EPHX1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
|
|
G |
Erap1 |
endoplasmic reticulum aminopeptidase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ERAP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:1,410,877...1,449,734
Ensembl chr 2:1,410,934...1,449,733
|
|
G |
Erf |
Ets2 repressor factor |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ERF mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:82,112,449...82,120,902
Ensembl chr 1:82,112,449...82,120,902
|
|
G |
Esr2 |
estrogen receptor 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ESR2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
Esrra |
estrogen related receptor, alpha |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ESRRA mRNA |
CTD |
PMID:23166782 |
|
NCBI chr 1:222,168,729...222,178,842
Ensembl chr 1:222,168,730...222,178,725
|
|
G |
Esrrg |
estrogen-related receptor gamma |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ESRRG mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:106,063,799...106,683,353
Ensembl chr13:106,463,368...106,683,436
|
|
G |
Etnppl |
ethanolamine-phosphate phospho-lyase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ETNPPL mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:235,738,377...235,760,351
Ensembl chr 2:235,738,416...235,760,352
|
|
G |
Etv1 |
ETS variant transcription factor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ETV1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 6:58,467,215...58,558,640
Ensembl chr 6:58,467,254...58,558,631
|
|
G |
Etv5 |
ETS variant transcription factor 5 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ETV5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:82,194,657...82,252,145
Ensembl chr11:82,194,657...82,252,139
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
decreases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EZH2 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EZH2 protein [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in decreased expression of EZH2 mRNA; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in decreased expression of EZH2 protein; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA] |
CTD |
PMID:21903722 |
|
NCBI chr 4:77,284,404...77,347,011
Ensembl chr 4:77,284,404...77,347,011
|
|
G |
F2rl2 |
coagulation factor II (thrombin) receptor-like 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of F2RL2 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 2:26,240,385...26,245,533
Ensembl chr 2:26,240,385...26,245,533
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FABP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
|
|
G |
Fads1 |
fatty acid desaturase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FADS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:226,234,034...226,249,118
Ensembl chr 1:226,234,074...226,249,138
|
|
G |
Fam155a |
family with sequence similarity 155, member A |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FAM155A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:85,528,126...86,053,447
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FASLG protein |
CTD |
PMID:16709600 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fbln1 |
fibulin 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FBLN1 mRNA |
CTD |
PMID:15774544 |
|
NCBI chr 7:126,096,793...126,176,468
Ensembl chr 7:126,096,793...126,176,468
|
|
G |
Fbxo32 |
F-box protein 32 |
multiple interactions |
ISO |
[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of FBXO32 mRNA; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of FBXO32 mRNA] |
CTD |
PMID:23275455 |
|
NCBI chr 7:98,065,664...98,098,071
Ensembl chr 7:98,063,735...98,098,268
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDFT1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:46,339,248...46,367,302
Ensembl chr15:46,339,249...46,367,302
|
|
G |
Fdx1 |
ferredoxin 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDX1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:56,373,729...56,393,199
Ensembl chr 8:56,373,723...56,393,233
|
|
G |
Fdxr |
ferredoxin reductase |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDXR protein Hydrocarbons, Chlorinated inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDXR protein] |
CTD |
PMID:24740604 |
|
NCBI chr10:103,817,724...103,826,413
Ensembl chr10:103,817,704...103,826,448
|
|
G |
Fer1l6 |
fer-1-like family member 6 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FER1L6 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 7:98,399,207...98,555,215
Ensembl chr 7:98,432,024...98,553,096
|
|
G |
Fgf10 |
fibroblast growth factor 10 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FGF10 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 2:51,673,480...51,747,533
Ensembl chr 2:51,672,722...51,750,369
|
|
G |
Fgf13 |
fibroblast growth factor 13 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FGF13 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:142,053,648...142,589,274
Ensembl chr X:142,053,654...142,248,369
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FGF9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:38,341,657...38,386,945
Ensembl chr15:38,341,089...38,387,316
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FHL2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:49,920,611...49,994,906
Ensembl chr 9:49,920,854...49,950,093
|
|
G |
Flot1 |
flotillin 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FLOT1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr20:3,427,890...3,438,418
Ensembl chr20:3,427,880...3,438,396
|
|
G |
Flot2 |
flotillin 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FLOT2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:65,304,901...65,329,332
Ensembl chr10:65,304,902...65,329,312
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FN1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 protein; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of IGFBP1 protein]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of PRL protein]; Hydrogen Peroxide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 mRNA]; Hydrogen Peroxide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 protein] |
CTD |
PMID:16709600 |
|
NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] inhibits the reaction [Hydrogen Peroxide results in increased expression of FOXO3 mRNA]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] inhibits the reaction [Hydrogen Peroxide results in increased expression of FOXO3 protein]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA] |
CTD |
PMID:16709600 |
|
NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
|
|
G |
Foxr1 |
forkhead box R1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FOXR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:48,754,300...48,762,765
Ensembl chr 8:48,754,736...48,762,342
|
|
G |
Fras1 |
Fraser extracellular matrix complex subunit 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FRAS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:14,438,392...14,853,016
Ensembl chr14:14,439,082...14,689,554
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
increases expression multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FSHB mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FSHB protein Tetrachlorodibenzodioxin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FSHB mRNA] |
CTD |
PMID:8404651 PMID:10746652 PMID:21467749 |
|
NCBI chr 3:98,088,321...98,092,131
Ensembl chr 3:98,088,324...98,092,131
|
|
G |
Fzd10 |
frizzled class receptor 10 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FZD10 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:31,757,407...31,760,604
Ensembl chr12:31,757,407...31,760,604
|
|
G |
Fzd4 |
frizzled class receptor 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FZD4 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr 1:153,589,471...153,598,376
Ensembl chr 1:153,589,471...153,598,375
|
|
G |
Fzd7 |
frizzled class receptor 7 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FZD7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:66,305,731...66,308,550
Ensembl chr 9:66,305,731...66,308,550
|
|
G |
Gabbr2 |
gamma-aminobutyric acid type B receptor subunit 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GABBR2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:62,276,100...62,621,737
Ensembl chr 5:62,276,100...62,621,737
|
|
G |
Gabra4 |
gamma-aminobutyric acid type A receptor subunit alpha 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GABRA4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:39,154,072...39,230,994
Ensembl chr14:39,154,529...39,231,695
|
|
G |
Gabrg1 |
gamma-aminobutyric acid type A receptor subunit gamma 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GABRG1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:39,964,502...40,051,306
Ensembl chr14:39,964,588...40,049,354
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of GADD45A mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of GADD45A protein |
CTD |
PMID:16709600 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Galnt12 |
polypeptide N-acetylgalactosaminyltransferase 12 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GALNT12 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 5:62,718,733...62,751,345
Ensembl chr 5:62,718,787...62,750,145
|
|
G |
Galr1 |
galanin receptor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GALR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:79,243,009...79,258,570
Ensembl chr18:79,243,009...79,258,570
|
|
G |
Gap43 |
growth associated protein 43 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GAP43 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr11:58,624,198...58,717,916
Ensembl chr11:58,624,198...58,717,914
|
|
G |
Gck |
glucokinase |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GCK mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:86,149,146...86,191,589
Ensembl chr14:86,148,928...86,190,659
|
|
G |
Gcsam |
germinal center-associated, signaling and motility |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GCSAM mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:60,168,938...60,180,191
Ensembl chr11:60,170,985...60,180,118
|
|
G |
Gdf10 |
growth differentiation factor 10 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GDF10 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:10,250,508...10,262,383
Ensembl chr16:10,250,404...10,263,150
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GDF15 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:20,555,395...20,557,978
Ensembl chr16:20,555,395...20,557,978
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GFAP mRNA 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [ochratoxin A results in decreased expression of GFAP mRNA] |
CTD |
PMID:15994020 |
|
NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
|
|
G |
Gfpt2 |
glutamine-fructose-6-phosphate transaminase 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GFPT2 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr10:35,279,237...35,325,506
Ensembl chr10:35,279,236...35,325,508
|
|
G |
Gimap8 |
GTPase, IMAP family member 8 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GIMAP8 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:78,283,356...78,294,838
Ensembl chr 4:78,283,026...78,294,845
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GJA1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:37,876,650...37,889,097
Ensembl chr20:37,876,650...37,889,089
|
|
G |
Gjb2 |
gap junction protein, beta 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GJB2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:37,377,313...37,394,494
Ensembl chr15:37,377,316...37,383,277
|
|
G |
Gk |
glycerol kinase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GK mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:54,227,291...54,303,897
Ensembl chr X:54,227,397...54,303,864
|
|
G |
Glipr1 |
GLI pathogenesis-related 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GLIPR1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 7:54,767,828...54,778,823
Ensembl chr 7:54,767,827...54,778,848
|
|
G |
Glrx |
glutaredoxin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GLRX mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:2,606,032...2,615,944
Ensembl chr 2:2,605,996...2,615,944
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI2 protein] |
CTD |
PMID:19252090 |
|
NCBI chr 8:116,370,730...116,391,337
Ensembl chr 8:116,370,744...116,391,307
|
|
G |
Gnai3 |
G protein subunit alpha i3 |
multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI3 protein] |
CTD |
PMID:19252090 |
|
NCBI chr 2:210,896,779...210,934,733
Ensembl chr 2:210,896,656...210,934,749
|
|
G |
Gng2 |
G protein subunit gamma 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GNG2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:4,748,242...4,853,555
Ensembl chr15:4,850,122...4,853,555
|
|
G |
Gpr22 |
G protein-coupled receptor 22 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GPR22 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:51,012,421...51,021,253
Ensembl chr 6:51,011,426...51,019,407
|
|
G |
Gpr37 |
G protein-coupled receptor 37 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GPR37 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:51,822,163...51,844,228
Ensembl chr 4:51,822,153...51,844,331
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GPX1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Grb10 |
growth factor receptor bound protein 10 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GRB10 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:92,021,851...92,122,249
Ensembl chr14:92,021,851...92,117,923
|
|
G |
Grb14 |
growth factor receptor bound protein 14 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GRB14 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:50,937,403...51,054,447
Ensembl chr 3:50,937,669...51,054,378
|
|
G |
Grem2 |
gremlin 2, DAN family BMP antagonist |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GREM2 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr13:92,894,431...92,988,137
Ensembl chr13:92,894,431...92,988,137
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
multiple interactions |
ISO |
[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA; NR3C1 protein inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA] |
CTD |
PMID:23275455 |
|
NCBI chr10:42,441,723...42,760,200
Ensembl chr10:42,614,713...42,760,200
|
|
G |
Grin3a |
glutamate ionotropic receptor NMDA type subunit 3A |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GRIN3A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:64,928,620...65,073,012
Ensembl chr 5:64,928,620...65,073,012
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GSTA2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:85,640,081...85,645,621
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GSTM2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:210,778,041...210,782,807
Ensembl chr 2:210,720,704...210,782,856
|
|
G |
Gstm4 |
glutathione S-transferase mu 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GSTM4 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 2:210,834,013...210,839,242
Ensembl chr 2:210,833,884...210,839,295
|
|
G |
Has2 |
hyaluronan synthase 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HAS2 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 7:96,438,046...96,464,049
Ensembl chr 7:96,438,046...96,464,049
|
|
G |
Hbg1 |
hemoglobin subunit gamma 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HBG1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:168,992,841...168,994,219
Ensembl chr 1:168,992,722...168,994,253
|
|
G |
Hdac3 |
histone deacetylase 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HDAC3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:31,073,057...31,094,347
Ensembl chr18:31,073,058...31,094,303
|
|
G |
Hdac5 |
histone deacetylase 5 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HDAC5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:90,140,183...90,169,853
Ensembl chr10:90,140,183...90,151,042
|
|
G |
Hey2 |
hes-related family bHLH transcription factor with YRPW motif 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HEY2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:29,191,170...29,201,257
Ensembl chr 1:29,191,192...29,201,531
|
|
G |
Hlf |
HLF transcription factor, PAR bZIP family member |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HLF mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:77,836,352...77,918,656
Ensembl chr10:77,840,568...77,918,191
|
|
G |
Hmga1 |
high mobility group AT-hook 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMGA1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:7,132,501...7,140,155
Ensembl chr20:7,136,007...7,138,980
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMGCS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:52,427,351...52,445,082
Ensembl chr 2:52,431,601...52,445,055
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMOX1 mRNA 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [ochratoxin A results in increased expression of HMOX1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMOX1 mRNA] |
CTD |
PMID:15179140 PMID:15994020 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hnf4g |
hepatocyte nuclear factor 4, gamma |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HNF4G mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:100,225,880...100,372,710
Ensembl chr 2:100,225,888...100,372,252
|
|
G |
Hoxb9 |
homeo box B9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HOXB9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:84,119,772...84,124,963
Ensembl chr10:84,119,884...84,123,390
|
|
G |
Hpca |
hippocalcin |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HPCA mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:147,295,124...147,305,757
Ensembl chr 5:147,294,820...147,303,346
|
|
G |
Hs3st1 |
heparan sulfate-glucosamine 3-sulfotransferase 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HS3ST1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:75,880,410...75,881,346
Ensembl chr14:75,852,060...75,882,693
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
multiple interactions |
ISO |
4'-cyanobiphenyl-4-sulfonic acid (6-aminopyridin-2-yl)amide inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of and results in increased activity of HSD11B1 protein; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of HSD11B1 protein; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA; Hydrocortisone promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA] |
CTD |
PMID:23275455 |
|
NCBI chr13:111,946,626...111,996,536
Ensembl chr13:111,926,442...111,972,603
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
decreases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSD11B2 mRNA [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B2 protein |
CTD |
PMID:22079614 PMID:23275455 |
|
NCBI chr19:37,476,083...37,481,326
Ensembl chr19:37,476,095...37,481,307
|
|
G |
Hsd17b1 |
hydroxysteroid (17-beta) dehydrogenase 1 |
multiple interactions increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate promotes the reaction [bisphenol A results in decreased expression of HSD17B1 mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B1 mRNA |
CTD |
PMID:18815356 PMID:21273127 |
|
NCBI chr10:88,987,558...88,989,758
Ensembl chr10:88,987,558...88,989,757
|
|
G |
Hsd17b14 |
hydroxysteroid (17-beta) dehydrogenase 14 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSD17B14 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:101,541,266...101,551,059
Ensembl chr 1:101,541,266...101,551,059
|
|
G |
Hsd17b2 |
hydroxysteroid (17-beta) dehydrogenase 2 |
multiple interactions increases expression |
ISO |
bisphenol A inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B2 mRNA] [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] affects the expression of HSD17B2 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B2 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B2 protein |
CTD |
PMID:18815356 PMID:21273127 PMID:21610156 |
|
NCBI chr19:50,246,404...50,317,892
Ensembl chr19:50,246,402...50,317,891
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:1,579,319...1,610,745
Ensembl chr17:1,579,319...1,610,745
|
|
G |
Hsd17b4 |
hydroxysteroid (17-beta) dehydrogenase 4 |
multiple interactions |
ISO |
[4-nitro-3-cresol co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD17B4 protein |
CTD |
PMID:18336853 |
|
NCBI chr18:44,810,462...44,897,677
Ensembl chr18:44,810,388...44,897,640
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:88,288,116...88,308,019
Ensembl chr13:88,288,046...88,307,988
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions decreases expression increases expression |
ISO |
2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA]]; Triiodothyronine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSD3B1 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 protein |
CTD |
PMID:18815356 PMID:21726595 PMID:22079614 |
|
|
|
G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B2 mRNA [4-nitro-3-cresol co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of HSD3B2 protein; Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B2 mRNA] |
CTD |
PMID:18336853 PMID:22079614 PMID:22546480 |
|
NCBI chr 2:200,712,895...200,722,429
Ensembl chr 2:202,341,422...202,350,929
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSP90AA1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:135,107,262...135,112,793
Ensembl chr 6:135,107,271...135,112,775
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSPA1A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSPA5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSPA8 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:44,989,401...44,993,261
Ensembl chr 8:44,990,014...44,993,179
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSPH1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:6,322,685...6,341,898
Ensembl chr12:6,322,668...6,341,902
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Reactive Oxygen Species results in increased expression of ICAM1 mRNA]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA] |
CTD |
PMID:10495789 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Icam2 |
intercellular adhesion molecule 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ICAM2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:94,569,889...94,581,218
Ensembl chr10:94,569,890...94,576,512
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ID1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:148,214,623...148,216,715
Ensembl chr 3:148,215,540...148,216,718
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
increases expression |
ISO |
|